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1. Introduction 
Fas ligand (FasL, CD95L, Apo-1L, CD178, TNFSF6, APT1LG1) is the key death factor 
of receptor-triggered programmed cell death in immune cells. FasL/Fas-dependent 
apoptosis plays a pivotal role in activation-induced cell death, termination of immune 
responses, elimination of autoreactive cells, cytotoxic effector function of T cells and 
NK cells, and the establishment of immune privilege and tumor counterattack. A 
dysregulation of FasL expression has severe impact on the maintenance of immune 
homeostasis and defense. Moreover, it was recently shown that FasL serves as a 
costimulatory receptor for T cell activation. The molecular mechanisms underlying the 
multiple roles of FasL are completely unsolved. It is not known whether FasL ligation 
induces a "direct" signal, e.g. leading to a change in phosphorylation of the cytosolic 
part of the molecule, or whether the regulation of activation signals is a more "indirect" 
result of protein-protein-interactions. In the latter scenario, a unique polyproline region 
located in the membrane-proximal part of FasL was shown to be required for a 
directed transport and localization of FasL. Over the past few years, this group and 
others identified several FasL interacting molecules that all bind via Src homology 3 or 
WW domains to the proline-rich region of FasL. The detailed evaluation of cell-type or 
stimulation-dependent association of FasL with the numerous potential proline-rich 
region-interacting proteins will help to better position the molecule in the complex net 
work of signaling, cytoskeletal and transport elements.  
 
1.1. FasL: a death factor and signal transducer 
A death factor for immune cell cytotoxicity and immune system homeostasis 
The Fas ligand is a 281 amino acid long (approximal 40 kDa) type II transmembrane 
protein of the TNF family of death factors1. It was initially identified as the binding 
partner for CD95/Fas/Apo-1 with a primary death-inducing function. The binding of 
FasL to Fas transmits a signal to the cytoplasm that leads to activation of caspase 8 
which in turn initiates a cascade of caspase activation leading to morphological 
changes of the cells and nuclei, as well as to degradation of the chromosomal DNA2. 
The activity of FasL/Fas is best documented in the regulation of peripheral tolerance, 
associated with cytotoxic activity of T cells and NK cells and to terminate the immune 
response via activation-induced cell death (AICD) (Fig. 1.1.) 
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Fig. 1.1. FasL/Fas in immune system: cytototoxic effects and activation induced cell
death of T cells. Stimulation of activated T cells through the TCR/CD3 complex results in the
rapid up-regulation of FasL and Fas expression. FasL is used to destroy virus infected cells or
tumor cells. The binding of FasL to the surface-expressed Fas molecule on the same or on
neighboring cells triggers Fas dependent death signaling. Due to membrane folding or,
alternatively, FasL cleavaged by metalloproteases (MP), FasL/Fas interactions result in both
autocrine "suicide" and paracrine "fratricide". 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In mature T cells, FasL is expressed and regulated differentially in individual T cell 
subsets. On CD4+ cells, FasL appears as a transmembrane receptor of Thelper1 (and 
of some Thelper2) cells following T cell receptor (TCR) stimulation by antigen, anti-
TCR/CD3 antibodies, mitogenic lectins, bacterial superantigens or other stimuli such 
as phorbol esters and calcium ionophore treatment3,4. Since AICD can be efficiently 
blocked by using Fas-Fc fusion proteins in such cells, FasL was characterized as a 
major effector molecule in the AICD regulating the termination of T cell responses and 
preventing autoimmunity5-7. For CD4+ T helper2 cells, a reduced expression or 
absence of FasL under similar conditions was reported that explained resistance of 
such clones to AICD8,9. However, further mechanisms at the level of transcription or 
beyond have been suggested to render these T helper2 cells unresponsive to Fas-
mediated cell death4,10. Thus, several reports indicate a role for PI-3 kinase modifying 
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Fas-associated caspase activity11-13, for the Fas-associated phosphatase 1 (FAP1)14, 
or for a differential regulation of c-FLIPshort15,16 in the regulation of Th2-resistance. 
Besides, FasL is expressed in Natural Killer cells where it can be further upregulated 
by CD16 engagement or cytokines including IL-2 and IL-1217-20. Importantly, in 
cytotoxic T cells (and NK cells), FasL is expressed and synthesized upon primary 
stimulation and then directed to and stored in specialized secretory 
lysosomes/granules21,22. Such secretory vesicles also contain cytotoxic proteins such 
as poreforming perforin and granzyme-type proteases. Upon contact with a (e.g. virally 
infected) target cell, the TCR-derived signal will lead to a redistribution of cytoskeletal 
elements and result in the release of these cytotoxic molecules into the immunological 
synapse23. In theory this could be accompanied by a directed surface expression of 
FasL with binding to Fas on the target cell or, alternatively, shedding of FasL in the 
presence of a metalloproteinase. Similarly, although less well studied, high levels of 
intracellular FasL have been detected in monocytic cells with an inducible release 
upon activation by immune complexes, PHA, or superantigen24. 
During T cell development and maturation, FasL is discussed to be involved in 
negative selection in concert with other molecules including CD5, CD28 and CD4325. 
In this context, FasL is supposed to act as an effector molecule leading to the deletion 
of autoreactive Fas-positive thymocytes26. In contrast, other findings indicate that 
Fas/FasL effects are involved in peripheral but not thymic deletion of T lymphocytes27 
(reviewed in28). 
 
Immune privilege and tumor counterattack 
Although still a matter of debate, FasL-expression has been associated with the 
establishment of immune privilege and tumor survival29. As an indication of immune 
privilege, over the past years constitutive or inducible membrane expression of FasL 
was shown for numerous cell and tissue types including the eye30,31, testis32 and/or 
mature spermatozoa33, uterus and placenta34,35, lung36, thyrocytes37,38, keratinocytes 
(upregulated by UV-B light)39, CD68+-histiocytes in the dermis40, neutrophils41, mature 
erythroblasts42, breast epithelial and vascular endothelial cells43-45, astrocytes 
(upregulated by IL-1, IL-6, TNF-α and IFN-γ)46, microglia (downregulated by IFN-γ)47 
and intervertebral discs48. The assumption, however, that FasL also confers immune 
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privilege and organ transplants32,49 has been challenged by studies indicating a 
differential pro- or anti-inflammatory effect of FasL depending on the 
microenvironmental contex50. 
 
Moreover, the constitutive expression of relatively high levels of (trans)membrane 
(mFasL) or the secretion of soluble FasL (sFasL) is regarded as a mechanism to 
ensure tumor survival by blocking immune defense mechanisms50-56. Hahne and 
colleagues reported that although tumor-specific cytolytic T cells directed against well 
defined antigens are present in the population of tumor-infiltrating lymphocytes (TIL) or 
can even be detected in peripheral blood of melanoma patients, obviously the 
melanoma cells escape immune elimination57. When melanoma cells were analyzed 
for the expression, both mFasL (40 kDa) and the sFasL(27 kDa) were detected 
whereas normal melanocytes did not express FasL. Since melanoma TIL mostly 
showed an activated phenotype (expressing Fas), it was proposed that transformed 
melanocytes induce apoptosis of Fas-sensitive TIL. As a proof of principle, FasL-
positive mouse melanoma cells led to rapid tumor formation when injected into normal 
mice but to delayed tumor formation in Fas-deficient animals57. In this regard, tumors 
could generate their immune privileged microenvironment.  
 
Physiology and pathophysiology - genetic defects 
Under physiological conditions, FasL is implicated in the control of erythroid 
differentiation58, angiogenesis in the eye59, skin homeostasis60 and CTL-mediated 
killing of virally infected or transformed cells61. Furthermore, FasL expression can be 
induced in a variety of cell types by stress including heat shock, exposure to 
chemotherapeutic agents or radiation, growth factor withdrawal and viral infection62. If 
not controlled properly, many of these functions can lead to tissue destruction and on 
the long run to autoimmune diseases.  
 
The lymphoproliferation (lpr) and generalized lymphoproliferative disease (gld) are 
naturally occurring mutations in mice63,64. The lpr stain is characterized by an almost 
complete defect of Fas expression, the lprcg mutation allows the expression of a non-
functional protein. In the gld mouse, a missense mutation in the extracellular domain of 
FasL abrogates its function. The phenotype of these mice is similar with developing 
nephritis, hypergammaglobulinemia and antinuclear antibodies in addition to 
PART 1 -5- INTRODUCTION    
 
Table. 1.1. Phenotype and genetic basis of ALPS patients.  
lymphadenopathy. With age, these mice accumulate CD4-CD8-TCRαβ+ T cells in the 
peripheral lymphocytes.  
 
The phenotype of Fas-/- mice, obtained by targeted mutation65 is more severe than gld 
or lpr mice. In addition to massive production of lymphocytes, the Fas-null mice show 
substantial liver hyperplasia accompanied by the enlargement of nuclei in hepatocytes. 
Germline deletion of the FasL gene results in an unexpectedly severe phenotype66. 
FasL-/- mice exhibit an extreme splenomegaly and lymphadenopathy associated with 
lymphocytic infiltration into multiple organs and autoimmune disease that lead to the 
premature death at 4 months of age of >50% of the homozygous mice.  
 
In human, direct defects in FasL/Fas result in specific forms of autoimmune 
lymphoproliferative syndrome (ALPS). ALPS is defined by functional analysis of 
lymphocyte sensitivity to Fas-induced apoptosis in vitro. T cells from ALPS patients 
can exhibit complete Fas-induced apoptosis (ALPS 0), consequence of a complete 
expression deficiency, partial Fas-induced apoptosis defect associated with normal or 
slightly reduced Fas expression (ALPS I and II), and finally normal Fas-induced 
apoptosis (ALPS III). Phenotype and genetic basis of these functional groups are 
diverse (See a summary in table 1.1, adapted from Riuex-Laucat et al.67). Concerning 
FasL, loss of FasL gives rise to ALPS1b. This human genetic disease and its mouse 
model (gld) lead to a failure of apoptosis and aberrant T cell accumulation. 
A bidirectional signaling transducer in mature T cells and thymocytes 
A series of reports employing mice defective for FasL (gld) or Fas (lpr; lprcg) recently 
suggested a costimulatory or modulatory function in the context of T cell activation for 
FasL in both CD8+ and CD4+ T cells68-71. While CD4+ cells showed a reduction in 
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TCR/CD3-induced cell cycle progression and later entered apoptosis, CD8+ cells 
required the FasL-costimulation to rapidly progress through the cell cycle, resulting in 
proliferation and acquisition of cytolytic effector function68-71. In all studies published so 
far, FasL reverse signaling seems to require a concomitant TCR engagement. 
Besides, Boursalian and Fink recently described Fas Ligand as an accessory molecule 
during positive selection72. They reported that in some (but not all) strains of TCR 
transgenic mice on a gld-background, T cell development is severely impaired. 
However, only positive selection seems to be altered whereas negative selection and 
death by neglect are not affected. The nature of the costimulatory signal delivered 
through FasL is unknown, although the structure of FasL suggests signaling capacity 
(as discussed in detail below). FasL could serve as a costimulatory molecule to either 
directly interfere with TCR triggered signal or by interfering with classical costimulatory 
molecules such as CD28 (Fig. 1.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.2. FasL as a bifunctional membrane receptor. A. FasL trimers function as death factor
to trigger Fas-induced apoptosis via FADD and caspase activation. This is the key event during
activation-induced cell death, it plays a major role in target cell cytolysis, in the establishment of
immune privilege, and during tumor counterattack. B. FasL as a costimulatory molecule? By
virtue of assembling with a number of proteins (double-circled) required for TCR-dependent
activation, FasL may alter the TCR/CD3 stimulus in different ways. In such a scenario, FasL
could serve as a costimulatory molecule to either directly interfere with signal 1 given by the
TCR or by interfering with signal 2 given by classical costimulatory molecules such as CD28. 
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1.2. Regulation of transcription and differential sorting of FasL  
The signaling required for FasL message and protein induction in T cells follows the 
regular pathway of T cell activation with an early engagement of Src-type tyrosine 
kinases. In fact, inhibition of Src kinases blocks FasL expression in AICD-sensitive 
cells73. The TCR-triggered induction of FasL may also be altered by costimulatory or 
accessory signals. In some T cell clones ligation of CD4 interferes with the 
composition of the regular TCR-associated signaling complex74,75. As far as 
transcriptional regulation of FasL is concerned, many of the classical transcription 
factors have been shown to be involved under different conditions (see76 for review). 
NFAT, NF-κB, c-myc, IRF-1, Egr-3 mediate FasL induction upon T cell activation, e.g 
in the context of AICD77-81. Egr factors also contribute to FasL expression in double 
negative thymocytes82. These factors display different binding activities to Egr sites in 
the FasL promoter of Th1 and Th2 cells and thereby discriminate the two populations 
with regard to their AICD-sensitivities83. The AP-1 complex increases FasL message 
following cellular stress84 and forkhead transcription factors have been implicated 
upregulation and expression of FasL upon growth factor withdrawl76,85. 
 
In cytotoxic T cells and NK cells, newly synthesized FasL is targeted to so-called 
secretory lysosomes17. Upon recognition of an antigen presenting or target cell, those 
secretory lysosomes are transported to the immunological synapse, exhibiting their 
contents and membrane bound proteins to the site of interaction. In this regard the 
packaging of Fas ligand to secretory lysosomes ensures a rapid and accurate release 
of this protein to the immunological synapse23. FasL is not only expressed in cells of 
the hematopoietic lineage, but also in a number of non-hematopoietic cell types. 
However in most non-hematopoietic cells FasL is expressed directly on the plasma 
membrane without being first sorted to lysosomes86. The differential expression has 
important biological consequences i.e. in context of the establishment of immune 
privilege (see above).  
 
Unlike other proteins that are sorted to the lysosomal compartment by di-leucine or 
tyrosine-based sorting motifs87,88, Griffiths and colleagues convincingly showed that 
FasL is targeted to secretory lysosomes via the proline-rich domain (PRD)86. Upon 
transfection, the presence of the PRD is sufficient to sort FasL to secretory lysosomes 
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whereas deletion of the PRD, but not of tyrosine or di-leucine motifs in the tail of FasL 
(7Y-9Y-13Y and 29V-30L), results in surface expression86. A model of FasL sorting 
pathways in cells with secretory lysosomes versus conventional lysosomes is 
adapted86 and shown in Fig. 1.3. Although in the meantime a number of possible 
interaction partners of FasL have been identified, the exact molecular mechanisms 
guiding FasL either to the secretory lysosomes or the plasma membrane remain 
unknown. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.4. Structural characteristics  
The Fas ligand is a 281 amino acids (278 in the mouse) containing type II 
transmembrane protein belonging to the tumor necrosis factor (TNF)/nerve growth 
factor (NGF) family which includes TNF, lymphotoxin, CD40L, 4-1BBL, TRAIL, OX40L, 
CD27L, CD30L, TRANCE and others89. At the amino acid level, FasL is well 
conserved between species with the murine and human FasL being 76.9% identical 
and functionally interchangeable90.  
 
Fig. 1.3. Model of FasL sorting pathways in cells with secretory lysosomes versus
conventional lysosomes. FasL exists the biosynthetic pathway at the trans-Golgi network
(TGN). In secretory cells, a-SH3-domain-containing protein sorts FasL, via its proline-rich
domain, to the secretory lysosomes. The absence of this interaction in non-secretory cells
results in sorting of FasL to the plasma membrane via the default exocytosis pathway. Delivery
of FasL to the plasma membrane in hematopoietic secretory cells only occurs during activation
(e.g. stimulation via the TCR).  
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As mentioned before, the molecular basis for the postulated reverse signaling capacity 
of FasL and the exact regulatory molecules guiding FasL either to the secretory 
lysosomes or the plasma membrane still remain unknown. However, two motifs 
present in the cytoplasmic part of FasL are likely to be involved in the regulation of 
both processes: a casein kinase 1 (CK1) substrate motif and a proline-rich domain 
(PRD) (Fig 1.4.).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FasL as a substrate for a casein kinase? 
Most ligands of the tumor necrosis factor (TNF) superfamily are transmembrane 
proteins that share structurally related extracellular TNF homology domains (THDs) 
which bind to cystein-rich domains (CRDs) of their specific receptors (of the TNF-
receptor superfamily). Ligand/receptor interactions of these families orchestrate the 
organization and function of many facettes of the immune system. In general, they 
regulate key events in cellular activation, proliferation, differentiation, cell death and 
survival of immune cells and other tissues91. Since most of the TNF-family-members 
act as membrane-bound factors and require direct cell-to-cell contact, it seems 
obvious that ligand/receptor engagement works as a bidirectional. Thus, ligand-
transmitted costimulatory functions have been reported for several members of the 
Fig. 1.4. Structural features of FasL. Human FasL is a type-II transmembrane molecule with 281
amino acids. The N-terminal cytoplasmic part (aa 1-81) contains a specific "double" CK1 substrate
motif (CK1-S, aa 17-21). It also harbors the proline-rich domain (PRD, aa 37-70) which could
function as a docking site for SH3 and WW domain proteins. The transmembrane region spans aa
81-102. Within the extracellular part, several metalloprotease substrate sites (MP-S) have been
named to serve as cleavage sites for one or more metalloprotease (aa 109-115 (ELAELR),
S126/127L and K129/130Q). These cleavage sites are located outside the region that is required
for trimerization and self-assembly (SA). Thus, sFasL can also form trimers. The C-terminal TNF
homology domain (THD, aa 183-281) contains several putative N-glycosylation sites (aa 184, 250,
260) and the very C-terminal receptor binding site (RB) with a critical phenylalanin residue at
position 275.  
17-21
1 37 70 81 102 281
N
126/127
137 183
SA THDTMPRD C
CK1-S MP-S RB
intracellular domain extracellular domain
sFasL
184 250 260
275
(129/130)
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TNF superfamily in T cells, B cells and monocytes. In fact, the ligand-receptor-
complexes of CD70/CD27 (TNFSF7/TNFRSF7)92, CD153/CD30 
(TNFSF8/TNFRSF8)93,94, CD154/CD40 (TNFSF5/TNFRSF5)95-98, 4-1BB-L/CD137 
(TNFSF9/TNFRSF9)99,100, OX40L/CD134 (TNFSF4/TNFRSF4)101, TRANCE/RANK 
(TNFSF11/TNFRSF11)102, LIGHT/LIGHTR (TNFSF14/TNFRSF14)103-105 and the death 
factors TNF106, TRAIL (TNFSF10)107 and FasL (TNFSF6)68-71 were reported to convey 
such "retrograde" signals.  
 
Importantly, a bidirectional signaling capacity has been associated with those six out of 
16 TNF family members (CD27L, CD30L, CD40L, CD137L, TNFα and FasL) that 
contain a putative casein kinase 1 (CK1) substrate motif (-SXXS-). Since such 
phosphorylation sites are not present in any of the remaining TNF family members, it 
seems likely that reverse signaling involves a casein kinase. Moreover, a receptor-
triggered and CK1-dependent serine phosphorylation of the corresponding residues 
within membrane-bound TNF has been experimentally proven108. In case of FasL, the 
membrane distal N-terminus of the molecule in fact contains a unique "double" CK1 
substrate site (amino acids 17-21 in man (-SSASS-) and 17-22 in mice (-SSATSS-)). 
The presence of such a double motif (-S(P)XXS-) indicates a role for an additional 
kinase to regulate the sensitivity of the site for CK1 by phosphorylation of the first 
serine residue108. Clearly, so far no data are available that demonstrate the 
involvement of a kinase or phosphatase in the regulation of FasL reverse signal 
transduction.  
 
The proline-rich domain (PRD) as a protein-docking site of FasL  
The second striking feature of the cytoplasmic tail of FasL is a  proline-rich domain 
(PRD) that spans amino acids 37-70 of the human FasL (Fig. 1.4.). In contrast to the 
CK1 motif, this PRD region is absolutely unique among all members of the TNF family, 
and thus may play a major role in the biology of FasL. Since proline-rich region bind to 
SH3- or WW-domain containing proteins109, it seems likely that the PRD region of 
FasL functions as a docking site for proteins that regulate trafficking and expression 
and maybe signaling of FasL110. In fact, it was found several years ago that peptides 
corresponding to the PRD of the murine FasL (aa 40-77) were able to selectively 
interact with the SH3 domain of the Src-related kinase p59fyn(T)111. From this it was 
suggested that FasL membrane expression is primarily regulated through an 
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activation-independent SH3-mediated association with p59fyn(T). In 1996, Hachiya and 
coworkers deposited several protein fragments in the NCBI database that were found 
to interact with FasL in a yeast two-hybrid screen. Although these "Fas-ligand 
associated factors" (FLAF1-3 - AAB93495, AAB93496, AAB93497) contained either a 
WW domain (FLAF1) or one or more SH3 domains (FLAF2,3), no further results were 
published except a note that FLAFs might regulate FasL stability. Sequence 
comparison with novel entries in the databases reveals that FLAF-1 forms part of the 
formin binding protein 11 (FBP11, also called the huntingtin-interacting protein HYPA), 
FLAF2 is part of the c-Cbl-associated protein SH3P12 = "sorbin and SH3 domain 
containing 1" (containing 3 SH3 domains), and FLAF3 represents a portion of the 
BAI1-associated protein 2 (BAP2)-beta (with a single SH3 domain).  
 
1.5. Identification of interacting proteins 
Strategies to identify associated proteins with proline recognition domains  
As mentioned, proline-rich regions are prerequisite to form binding sites for specific 
SH3- or WW-type proline recognition domains. Studies from this group clearly indicate 
that FasL might interact with several other molecules in addition to Fyn and the poorly 
characterized FLAFs112. In order to identify proteins that interact with the FasL PRD, 
two different protein-based screening approaches were used.  
 
First, a large panel of SH3 and WW domains expressed as GST fusion proteins were 
checked for their ability to precipitate FasL from stable transfectants and T 
lymphoblasts112. These analyses revealed that in addition to the SH3 domain of p59fyn, 
a number of other SH3 or WW modules are also capable to effectively and specifically 
interact with the full length FasL overexpressed in transfectants and inducibly 
expressed in stimulated human T lymphocytes. The identification of various other Src-
related kinases and different SH3 adapter proteins of the Grb2-family, PI 3-kinase, Nck 
and Phox-47 and the WW domain proteins FE65, FBP11 and dystrophin as putative 
FasL-interacting molecules, opened new insights into the potential of FasL to regulate 
and modulate activation processes in T cells and other FasL expressing cells. In the 
context of reverse signaling, the long and - as we now know - by far not complete list 
of putative FasL interacting proteins opens the field for speculations and models.  
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As a second approach to identify FasL interactors, different variants of the intracellular 
region of human FasL were constructed as GST fusion proteins and used to 
precipitate binding partners from T cell lysates. The precipitates were separated by 
two dimensional gel electrophoresis and sequence information obtained by MALDI-
TOF-based peptide finger print analyses. According to these analyses, Grb2, 
PACSIN2, FBP17 β-tubulin and actin were found in precipitates formed with fusion 
proteins containing the whole cytoplasmic region including the PRD113. Grb2 is a well-
defined adapter protein that plays a pivotal role in growth factor receptor as well as 
TCR signaling. After TCR-activation the Grb2–Sos complex is recruited to the 
phosphorylated transmembrane adapter, linker for activated T-cells (LAT), thereby 
triggering the Ras/MAPK pathway and leading to transcription of a whole range of 
proteins needed for T-cell activation and differentiation114. The interaction of Grb2 and 
FasL was confirmed by this group113.  
 
PACSIN2 and FBP17 
As mentioned, with FBP17 and PACSIN2, we identified two new potential FasL 
binding partners in human T cells. PACSIN2 is a 53 kDa human splice variant of the 
rat Syndapin II, a member of a family of cytosolic adapter proteins that link clathrin-
dependent-endocytosis to the actin cytoskeleton and are involved in the regulation of 
vesicular traffic115-119. To date, three PACSINs are known, all of which contain 
phosphorylation sites for casein kinase 2 and protein kinase C (the name PACSIN 
refers to "protein kinase C and casein kinase substrate in neurons"). In contrast to the 
ubiquitously expressed PACSIN2, PACSIN1 was previously not detected in cells other 
than neurons. In terms of function, PACSIN isoforms specifically interact with Sos, 
thereby regulating actin dynamics via MAP kinase signaling120. In the context of FasL, 
PACSIN2 could be involved in the reorganization of the cytoskeleton and in trafficking 
of cytoplasmic vesicles leading to storage and regulation of extrusion of FasL. The 
potential association of PACSINs with the GEF Sos may also suggest a role in 
downstream signaling to MAP-Kinases120.  
 
Formin binding protein 17 (FBP17) is a 72 kDa protein that belongs to the large 
heterogeneous family of formin binding proteins. In association with the various 
formins, these proteins also regulate the organization and assembly of the actin 
cytoskeleton and are involved in orchestrating cell motility, adhesion and 
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cytokinesis121. Fuchs et al. showed that FBP17 is widely expressed in a variety of 
human tissues122. They demonstrated the interaction of FBP17 with sorting nexin 
(SNX2) and thus provided a link between MLL, a gene connected to myelogenous 
leukemia, and the epidermal growth factor receptor (EGFR) pathway. In general, SNX-
proteins are crucial molecules involved in directed protein trafficking and lysosomal 
targeting123. Therefore, association of FasL with FBP17 could represent once more an 
alternative mode of lysosomal transport of FasL and also point to a signaling crosstalk 
between the death factor and the EGFR-pathway.  
 
Interestingly, PACSIN2 and FBP17 share an overall modular composition with an N-
terminal FCH (Fes/CIP4 homology) domain, a central coiled-coil region and a C-
terminal SH3 domain which interacts with FasL113. FCH domain was first identified in 
cell division control protein 15 from fission yeast where after the onset of mitosis, it 
forms a ring-like structure which co-localizes with the medial actin ring. From yeast to 
man in most cases it may mediate cytoskeletal rearrangements, vesicular transport 
and signal transduction124-126. 
 
NCK 
Nck-1 is a 47 kDa cytosolic adapter protein which is built of one N-terminal SH2 and 
three SH3 domains. The well known function of Nck-1 is the regulation of cytoskeletal 
assembly through interaction with the Wiskott-Aldrich syndrom protein WASP127, the 
WASP interacting protein WIP128, WASP-family verprolin homologous protein 
WAVE1129, the Centaurin-α family of PIP3 binding proteins130, the p21-activated 
kinase PAK1131, the ε-chain of CD3132 and others. This cytoskeletal association may 
also play a role in FasL transport to the cell membrane. In this context, Nck-1 seem to 
be a crucial regulator of protein assembly and cytoskeletal reorganisation during the 
formation of the immunological synapse upon TCR ligation132. Besides, Nck was 
shown to constitutively associate with the active γ2 isoform of casein kinase 1 (CK1-
γ2)133 and therefore could be involved in recruitment of the kinase into proximity of 
FasL as a putative substrate.  
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2. Aims of the study 
Although FasL has been identified ten years back, we are still far from understanding 
the complex biology of the molecule. FasL is found in both immunologically active and 
immune privileged tissues and in immune cells as well as in tumor cells. The 
regulation of expression and the function seem to be cell-type-specific. This concerns 
both the cytotoxic potential and the putative co-stimulatory signaling capacity. In 
mature human T cells, the evidence of reverse signaling through FasL and the 
molecular mechanisms involved need to be identified. The analyses of FasL 
associated casein kinase activity may shed light on this function. In terms of FasL 
transport and storage, the identification of the PRD-interacting proteins will help to 
position the molecule in the complex cytoskeleton and transport network. Previous 
work from this group identified a relatively large numbers of putative interactors for 
FasL. The main focus of the present study was the detailed analysis of several of 
these interactions in vitro and in vivo.  
 
1. Retrograde signaling of FasL in human T cells. 
In order to analyze the retrograde signaling of FasL in human T cell populations, 
suitable culture and stimulation conditions had to be worked out and adapted for 
different T cell subpopulation. In order to mimic the FasL-ligation, a FasFc fusion 
protein had to be constructed and produced. Readout for effects of FasL-engagement 
were proliferation, cell cycle progression, expression of activation markers, cell death 
and others. 
 
2. Storage of FasL in secretory lysosomes 
When investigating the FasL expression in activated cells, it became obvious that this 
death factor was located in discrete subcellular compartment that could be later 
defined as lysosomes. Therefore, the role of the different proteins from the two 
screens for interactors needed to be exploited. In the context of organelle transport, 
since PACSIN2 and its relatives are known to be involved in vesicle transport in other 
system, the focus was set on the analysis of interaction of FasL and proteins of the 
FCH/SH3 family. 
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3. Leading FasL to the immunological synapse 
Nck had been identified as an interactor of FasL. In 2002, it was described that Nck 
mediates recruitment of cytoskeletal elements to the TCR. Thus, we aimed at looking 
in detail into the association of Nck with FasL. To this end, co-transfection strategies 
as well as in vivo analyses of T cells encountering their target cells had to be 
established and investigated.  
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3. Materials and methods 
3.1. Materials 
Cell biology 
3.1.1. Cells  
Human peripheral blood mononuclear cells (PBMC) and T cell subpopulation were 
isolated from buffy coat preparations from healthy donors obtained from the 
department of Transfusion Medicine, UK-SH, Kiel. Staphylococcal enterotoxin (SE) 
superantigen A-reactive T cell clones (12603, 12623, 12632, 12625), CD8+ T cell lines 
(CD8-K, CD8-L), the γδ T cell line (EP3) and EBV-transformed lymphoblastoid B cell 
lines (EBV-O, EBV-M) were established in this laboratory. We also used Jurkat 
leukemia cells (J16 or Je 6.1) and clones derived thereof. The variant clones mainly 
differed in the expression of Fas and FasL. JM301 was described earlier134 as Fas+ but 
Fas-resistant. J16 Rapo is a Fas-lacking subclone of J16. Both Fas resistant variants 
were used to establish stable transfectants introducing the FasL molecule (see section 
3.2.4.). KFL-9 is a FasL transfectant established from K562 human erythroleukemia 
cells by Dr. David Kaplan, OH, USA. For transient protein expression, 293T (human 
embryonic kidney, SV40 transformed, ATCC: CRL-1573), HeLa (human cervix 
adenocarcinoma, ATCC: CCL-2), HaCaT (human skin keratinocytes), HUT78 (human 
T lymphoma. ATCC: TIB-161) and RBL2H3 (Rat basophilic leukaemia) cells were 
selected on the basis of their tissue origin representing hematopoietic or non-
hematopoietic cell types. For FasFc fusion protein production, human embryonic 
HEK293 cells were used. Besides, a human malignant melanoma fibroblast cell line 
MeWo was used as target cell in a cytotoxicity assay with  γδ T cells. 
 
3.1.2. Media and buffers  
Cell culture   
Standard cell culture media  
RPMI1640 (with 25 mM N-2-hydroxyethylpiperazine-N’-2-
ethanesulfonic acid (HEPES) and L-Glutamine) 
Invitrogen, Karlsruhe 
  
DMEM (Dulbeccos minimum essential medium) Invitrogen, Karlsruhe 
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Penicillin (10000 U)/Streptomycin (10000 µg)  Biochrom AG, Berlin 
  
FBS (fetal bovine serum) Invitrogen, Karlsruhe 
(Inactivated for 30 min at 56°C, 0.22 µm filtered)  
  
AB serum pool  
(Inactivated for 30 min at 56°C, 0.22 µm filtered)  
  
L-Glutamine (200 mM)  Biochrom AG, Berlin 
  
Media were supplemented with 1% (v/v) Penicillin/Streptomycin and 5-10% (v/v) FBS or 
AB serum pool as indicated in the respective section. To DMEM medium, additional 1% 
(v/v) L-Glutamine was added.  
  
Serum free medium   
FreeStyleTM  293T expression medium Invitrogen, Karlsruhe 
  
Freezing medium   
Culture medium with 20% FBS (v/v) and 10% (v/v) Dimethylsulfoxid (DMSO, Merck, 
Darmstadt) 
  
Phosphate-buffered saline (PBS) Biochrom AG, Berlin 
  
Typsin-EDTA (0.5%/0.2% (w/v)) Biochrom AG, Berlin 
  
Cell separation   
Ficoll (1.077 g/ml) Biochrom AG, Berlin 
  
Sheep red blood cells (SBRC)  Invitrogen, Karlsruhe  
  
Test Neuraminidase  Dade Behring, Marburg
  
Rabbit Complement Cedarlane Lab, CA 
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Calcium-phosphate transfection  
BES (2×)   
N, N-bis (2-hydroxyrthyl)-2-aminorthanesulfonic acid (BES) 50 mM Merck, Darmstadt 
Sodium Chloride (NaCl) 280 mM Merck, Darmstadt 
Sodium phosphate dibasic (Na2HPO4)  1.5 mM Merck, Darmstadt 
Adjusted to pH 6.95 and 0.22 µm filtered    
   
HBS (2×)   
HEPES 50 mM Merck, Darmstadt  
NaCl 280 mM Merck, Darmstadt 
Na2HPO4 1.5 mM Merck, Darmstadt 
Adjusted to pH 7.17 and 0.22 µm filtered   
   
Calcium chloride dihydrate (CaCl2, 10×)   
CaCl2 2.5 M Merck, Darmstadt 
ddH2O  Braun, Melsungen 
   
Immune cellular staining    
Poly-L-lysine (MW>300,000) Sigma, Munich 
  
PEM buffer (2×)   
Piperazine-N, N’-bis(2-ethanesulfonic acid), PIPES 200 mM Merck, Darmstadt 
Magnesium chloride (MgCl2) 2 mM Merck, Darmstadt 
Ethylene glyco-bis (β-aminoethylether)-N, N, N’, N’-
tetraacetic acid, EGTA 
2 mM Merck, Darmstadt 
Adjusted to pH 6.5 and 0.22 µm filtered   
   
Borate buffer (2×)   
Sodium borate  200 mM Merck, Darmstadt 
MgCl2 2 mM Merck, Darmstadt 
Adjusted to pH 11 and 0.22 µm filtered   
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Triton X-100 stock solution    
Triton®X-100 10% (v/v) Merck, Darmstadt 
ddH2O  Braun, Melsungen 
 
Fixation buffer- 3% paraformaldehyde (PFA)  
3 g PFA (Merck, Darmstadt) were added to 50 ml ddH2O with 1-2 drops 10 N NaOH and 
agitated in a 70°C water bath until the solution cleared. Upon cooling, pH was adjusted 
to pH 7.0. The same volume of 2× PEM buffer or 2× borate buffer was then added. 
 
Permeabilization buffer- 1% (v/v) Triton X-100  
1: 10 diluted from stock solution with PBS 
   
Washing buffer- PBST    
0.01% Triton (v/v) in PBS   
 
Blocking buffer   
0.2% (w/v) Bovine serum albumin (BSA, Carl Roth, Karlsruhe,) in PBST 
    
Mounting medium    
Solutions in Slowfade® Light Anti-Fade Kit (MoBiTec, Göttingen)  
 
Immune surface staining  
Washing buffer  
1% BSA (w/v) in PBS with 0.1% sodium azide (NaN3, w/v, Merck, Darmstadt) 
   
Fixation buffer  
1% PFA (w/v) in PBS, store at 4°C in the dark 
   
DNA staining for cell cycling analysis  
Stock solution 
I. 0.5 M EthyleneDiamineTetraAcetic acid (EDTA) 
Titriplex®III  186.1 g Merck, Darmstadt 
ddH2O  Braun, Melsungen 
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Adjusted to pH 8.0   
   
II. RNase A 1 mg/ml Qiagen, Hilden 
   
III. propidium iodide (PI) 1 mg/ml Serva, Heidelberg 
 
Washing buffer  
PBS with 5 mM EDTA 
 
Fixation buffer 
100% Ethanol (Merck, Darmstadt)   
   
Staining solution   
50 µg/ml PI, 40 µg/ml RNase A in washing buffer 
 
3.1.3. Antibodies (listed as final concentration or dilution factor) 
Cell stimulation  
α-CD3 (OKT3) 1-10 µg/ml  Janssen-Cilag, Neuss 
α-CD28  5 µg/ml  BD Pharmingen, Heidelberg 
α-FasL 5G51 10 µg/ml Dr. K. Schulze-Osthoff, Düsseldorf 
   
Crosslinking    
Rabbit anti-mouse IgG 1 µg/ml Jackson ImmunoResearch 
Laboratories, West Grive, PA
α-human IgG, Fc specific 2.5-5.0 µg/ml Sigma-Aldrich, Munich 
   
Cell separation    
α-CD4 40 µg/ml  Dianova, Hamburg 
α-CD8 40 µg/ml  Dianova, Hamburg 
α-CD56 6 µg/ml  BD Pharmingen, Heidelberg 
 
Immune cellular staining   
I. Primary antibodies  
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α-FasL (CD178, NOK-1, IgG1a) 1:50 BD Pharmingen, Heidelberg 
α-Nck (IgG2b) 1:50 BD Pharmingen, Heidelberg 
α-myc (IgG1) 1:100 Invitrogen, Karlsruhe 
α-myc (IgG2a) 1:200 Cell Signaling, Frankfurt 
α-Lamp1 (IgG2b) 1:50 BD Pharmingen, Heidelberg 
α-CathepsinD (rabbit polyclonal antibody, pAb) 1:75-1:100 Calbiochem, Bad Soden 
   
II. Fluorescence conjugated secondary antibodies 
goat anti-mouse/Alexa Fluor 488 1:500 MoBiTec, Göttingen 
goat anti-mouse/Alexa Fluor 546 1:500 MoBiTec, Göttingen 
goat anti-rabbit/Alexa Fluor 488 1:500 MoBiTec, Göttingen 
donkey anti-mouse/CY5 1:75 Dianova, Hamburg 
donkey anti-rabbit/Rhodamine 1:75 Santa Cruz, Heidelberg 
   
Immune surface staining (concentration according to manufacturer’s instructions) 
I. Primary antibodies 
α-CD3/Phycoerythrin (PE)  BD Pharmingen, Heidelberg 
α-CD4/fluorescein isothiocyanate (FITC) BD Pharmingen, Heidelberg 
α-CD8/FITC  BD Pharmingen, Heidelberg 
α-CD56/FITC  BD Pharmingen, Heidelberg 
α-Fas (CD95)/ PE  BD Pharmingen, Heidelberg 
α-FasL/biotin  BD Pharmingen, Heidelberg 
α-FasL/PE  Caltag, Hamburg 
α-CD25/PE  BD Pharmingen, Heidelberg 
α-CD69/PE  BD Pharmingen, Heidelberg 
IgG1/PE  BD Pharmingen, Heidelberg 
IgG2a/FITC  BD Pharmingen, Heidelberg 
 
II. Fluorescence-conjugated secondary antibodies/reagents 
Goat anti-mouse/PE (gam-PE)  BD Pharmingen, Heidelberg 
Streptavidin Phycoerythrin (SA-PE)   BD Pharmingen, Heidelberg 
Avidin-FITC  BD Pharmingen, Heidelberg 
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3.1.4. Factors and other reagents (listed as final concentration) 
Recombinant Interleukin-2 (rIL-2) 10 U /ml Chiron GmbH, Marburg 
Phytohemagglutinin (PHA) 0.5 µg/ml Murex Biotech, England 
Staphylococcal enterotoxin superantigen 
A, B, C, D, E (SEA, B, C, D, E) 
0.5 ng/ml Toxin Technologies, FL, USA 
Phorbol-12-myristate-13-acetate (TPA/PMA) 5-10 ng/ml Sigma-Aldrich, Munich 
Ionomycin 500 ng/ml Calbiochem, Darmstadt 
Bacteria phospho-antigen, BrHPP 200 nM Dr. Fournie, Toulouse, France 
Cytochalasin D 10 µM  Calbiochem, Darmstadt 
Latrunculin A  5 nM Sigma-Aldrich, Munich 
FasFc 25-50 µg/ml See section 3.2.8 
Human IgG-Fc fragment 25-50 µg/ml Bethyl, TX, USA 
Hygromycin B 300 mg/ml Merck, Darmstadt 
Lysotracker Red DND-99 50-100 nM MoBiTec, Göttingen 
Rhodamine phalloidin 1 unit MoBiTec, Göttingen 
Chromium-51 (51Cr) 50 µCi Amersham, Freiburg 
Methyl 3H thymidine (3H TdR) 1 µCi Amersham, Freiburg 
 
Molecular Biology 
3.1.5. Primers  
The primers were designed either encoding fragments of or full length target genes 
according to the sequence database in Gene Bank. The primers were used for regular 
or cloning PCR (as listed in Table 3.1.1.). For cloning purposes, flanking restriction 
sites were added to allow for unidirectional inserting. 
 
Table 3.1.1. Primers used for PCR 
1. Primers for regular PCR 
Name Sequence (5’-3’) 
s: 5’ Tgg CAg AAC TCC gAg AgT CTA 3’ FasL fragment  
(Exon1-Exon 4)  as: 5’ CAC Tgg gAT TgA ACA CTg 3’ 
s: 5’ gAC CCC TTC ATT gAC CTC 3’ GAPDH fragment  
(codon 3199-4003)  as: 5’ CCA AAg TTg TCA Tgg ATg 3’ 
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2. Primers for cloning PCR 
Name 
(GeneBank no.) 
Sequence (5’-3’) RE ∗ 
s: CCCAAgCTT - gC ACC ATg gAT Tgg ggC ACT gAg HindIII (1) CIP4 
(AJ000414) as: ATAAgAATgCggCCgC - TT gAg CgT gAC TCg gAg gTA NotI  
    
s: CgggATCC - ACC ATg ATg CCC CAg CTg Cag BamHI (1) CD2BP1 
(AF038062/3) as: CggAATTC - AAg CTT CTC CAg gTA ggA ACC EcoRI (4) 
    
s: CgggATCC - ACC ATg TCC AgC TCC TAC gAT g BamHI PACSIN1 
(AF242529) as: CggAATTC - gAT AgC CTC CAC gTA gTT ggC Ag EcoRI 
(1) 
    
PACSIN2 s: CCggAATTC - gTC TgT CAC ATA TgA TgA TTC EcoRI 
(NM_00729) as: CgggATCC - gAA ATg TCT gTC ACA TAT g BamHI 
(2) 
    
s: CCggAATTC - gTC TgT CAC ATA TgA TgA TTC EcoRI PACSIN2P478L 
(NM_00729) as: CCggATCC-TCA CTg gAT CgC CTC CAC ATA ATT TgC gAg gTA 
TAg gCC 
BamHI 
(2) 
    
s: CggAATTC - ACC ATg gCT CCA gAA gAg gAC EcoRI PACSIN3 
(AF149825) as: CCgCTCgAg - ggC ACC CAC ACA CTC CAC gTA g XhoI 
(1) 
    
s: CCCAAgCTT - ACA CCA TgA gTT CTg AAT gTg ATg gTg HindIII SH3P12 
(AF136381) as: CggAATTC - TAg ATA CAA Agg TTT TAC ATA gTT gC EcoRI 
(1) 
    
s: CgggATCC - ACC ATg TCT TTg TCT CgC BamHI BAP2-β 
(BC014020) as: CggAATTC - CAC TgT ggA CAC Cag CgT gC EcoRI 
(1) 
    
s: CggAATTC - TgC CAT gCA gCA gCC CTT CA EcoRI FasL 
(NM_000639) as: CgggATCC - AgC TTA TAT AAg CCg AAA AA Cg BamHI 
(3) 
    
s: CCCAAgCTT - ACA ACC ATg CTg ggC ATC Tgg ACC CTC HindIII Fas (M67454) 
(extracellular) as: CggAATTC - gTT AgA TCT ggA TCC TTC EcoRI 
(5) 
no. number; s: sense; as: anti-sense; RE: restriction endonucleus enzyme ∗ according to vector number 
in 3.1.6. 
 
 
 
 
PART 3 -24- MATERIALS AND METHODS 
 
3.1.6. Vectors  
TA cloning   
PCR2. 1 TOPO® TA cloning Invitrogen, Karlsruhe 
   
Bacteria expression   
pGEX2T (4) GST tag Pharmacia, Sweden 
   
Mammalian expression   
pcDNA3. 1/myc his A (1) C-terminal myc/his tag Invitrogen, Karlsruhe 
pEGFP C1 (2) C-terminal GFP tag Invitrogen, Karlsruhe 
pDsRed N1 (3) N-terminal DsRed tag BD Clontech, Heidelberg  
pcDNA3-hFc (5) C-terminal Fc tag Dr. H. Wajant, Frankfurt 
pEFBOS  Dr. B. Schraven, Magdeburg 
Hygromycin resistant vector  Dr. B. Schraven, Magdeburg  
 
3.1.7. Other constructs  
We also used some constructs that were kindly provided by other laboratories for 
transfection or purification fusion protein. The information of those constructs is listed 
in Table 3.1.2. and also published elsewhere (see references). 
 
Table 3.1.2. Constructs obtained from other laboratories 
Insert Vector References 
PACSIN1 pGEX 3X Dr. M. Plomann, Köln118 
PACSIN2  pGEX 2T Dr. M. Plomann, Köln118 
PACSIN2 p478l  pGEX 2T Dr. M. Plomann, Köln118 
PACSIN3  pGEX 3X Dr. M. Plomann, Köln118 
PACSIN2 pMyc-CMV Dr. M. Plomann, Köln118 
PACSIN1 pEGFP C1 Dr. M. Plomann, Köln118 
PACSIN3 pEGFP C1 Dr. M. Plomann, Köln118 
FBP17  PDsRed1-N1 Dr. U. Fuchs, Giessen122 
FBP17+myc PCDNA3.1/V5-His TOPO Dr. U. Fuchs, Giessen122 
FBP17-SH3 +myc  PCDNA3.1/V5-His TOPO  Dr. U. Fuchs, Giessen122 
Nck1  PCDNA3.1 Myc-His C Dr. L. Larose, Montreal, CA133,135 
Nck1 SH2 mutated PCDNA3.1 Myc-His C Dr. L. Larose, Montreal, CA133,135 
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Nck1 1st SH3 mutated PCDNA3.1 Myc-His C Dr. L. Larose, Montreal, CA133,135 
Nck1 2nd SH3 mutated PCDNA3.1 Myc-His C Dr. L. Larose, Montreal, CA133,135 
Nck1 3rd SH3 mutated PCDNA3.1 Myc-His C Dr. L. Larose, Montreal, CA133,135 
Nck1 all SH3s mutated PCDNA3.1 Myc-His C Dr. L. Larose, Montreal, CA133,135 
Nck1  pGEX Dr. L. Larose, Montreal, CA133,135 
Nck1 SH2  pGEX Dr. L. Larose, Montreal, CA133,135 
Nck1 1st SH3  pGEX Dr. L. Larose, Montreal, CA133,135 
Nck1 2nd SH3  pGEX Dr. L. Larose, Montreal, CA133,135 
Nck1 3rd SH3  pGEX Dr. L. Larose, Montreal, CA133,135 
Nck1 all SH3s  pGEX Dr. L. Larose, Montreal, CA133,135 
Nck1 1st SH3 mutated pGEX Dr. L. Larose, Montreal, CA133,135 
Nck1 2nd SH3 mutated pGEX Dr. L. Larose, Montreal, CA133,135 
Nck1 3rd SH3 mutated pGEX Dr. L. Larose, Montreal, CA133,135 
Nck1 all SH3s 1st SH3 mutated pGEX Dr. L. Larose, Montreal, CA133,135 
Nck1 all SH3s 2nd SH3 mutated pGEX Dr. L. Larose, Montreal, CA133,135 
Nck1 all SH3s 3rd SH3 mutated pGEX Dr. L. Larose, Montreal, CA133,135 
Nck1  CB6 GFP Dr. M. Way, London, UK136 
Nck1 W38K CB6 GFP Dr. M. Way, London, UK136 
Nck1 W143K CB6 GFP Dr. M. Way, London, UK136 
Nck1 W229K CB6 GFP Dr. M. Way, London, UK136 
Nck1 R308K CB6 GFP Dr. M. Way, London, UK136 
 
3.1.8. Enzymes  
Restriction Endonucleus Enzymes  
EcoRI New England Biolabs, Frankfurt 
BamHI New England Biolabs, Frankfurt 
XhoI Promega, Mannheim 
XbaI New England Biolabs, Frankfurt 
HindIII New England Biolabs, Frankfurt 
  
T4 ligase Promega, Mannheim 
  
Pfu DNA polymerase Promega, Mannheim 
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Klenow fragment Boehringer, Mannheim 
  
alkaline phosphatase (AP) Boehringer, Mannheim 
 
3.1.9. Buffers and other reagents 
Tris/acetate/EDTA (TAE, 50×)   
tris (hydroxymethyl)aminomethane (Tris)  242 g  
Boric acid 55 g  
0.5 M EDTA 40 ml Serva, Heidelberg 
ddH2O up to 1 liter  Braun, Melsungen 
 
1% agarose gel    
Agarose 1% w/v Merck, Darmstadt 
1×TAE   
 
Ethidium Bromide (EB, stock solution) 5 mg/ml Merck, Darmstadt 
use 0.5 µg per ml agarose solution   
   
Agarose gel sample buffer (10×)  Promega, Mannheim 
   
DNA -Molecular weight Standards   
1 Kb DNA ladder  Invitrogen, Karlsruhe 
100 bp DNA ladder  Invitrogen, Karlsruhe 
2-log DNA ladder with indicated concentration  New England Biolabs, 
Frankfurt 
   
Competent cells   
Subcloning Efficiency™ DH5 ™  Invitrogen, Karlsruhe 
 
3.1.10. Kits for molecular biology 
RNeasy® Mini Kit QIAGEN, Hilden 
QIAquick PCR Purification Kit QIAGEN, Hilden 
QIAquick Gel Extraction Kit QIAGEN, Hilden 
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QIAGEN® plasmid Mini and Maxi Kit QIAGEN, Hilden 
DyeEx spin Kit QIAGEN, Hilden 
Big-dyeTM terminal sequencing kit      Applied biosystems, Darmstadt
GeneAmp® RNA PCR Kit  Applied biosystems, Darmstadt
PCR Master Mix Promega, Mannheim 
 
Biochemistry 
3.1.11. Buffers and Reagents  
FasFc fusion protein purification 
Beads   
Protein A Sepharose CL-4B Beads  Amersham, Freiburg 
 
Start buffer (20 mM phosphate buffer, pH 7.0) 
a) 1 M sodium phosphate monobasic (NaH2PO4) stock solution 
NaH2PO4·H2O 68.995 g Merck, Darmstadt 
ddH2O 500 ml Braun, Melsungen 
1: 50 dilution before use (20 mM. pH 4.75-4.5), add 0.3M NaCl (8.766 g to 500 ml) 
 
b) 1 M sodium phosphate dibasic (Na2HPO4) stock solution  
Na2HPO4·2H2O 88.975 g Merck, Darmstadt 
ddH2O 500 ml Braun, Melsungen 
1: 50 dilution before use (20 mM, pH 9.3-8.9), add 0.3 M NaCl (8.766 g to 500 ml) 
Mix 20 mM NaH2PO4/Na2HPO4 with NaCl to pH 6.5 (around 68.5/31.5 ml) or pH 7.0 
(around 39/61 ml). Check by pH meter. 
 
Elution buffer (0.1 M Glycine-HCl buffer, pH 2.7) 
Glycine 3.275 g Carl Roth, Karlsruhe  
Adjusted to pH 2.7 with HCl, filled to 500 ml with ddH2O 
   
Neutralization buffer (1 M Tris-HCl buffer, pH 9.0) 
Tris 60.565 g Carl Roth, Karlsruhe 
Adjusted to pH 9.0 with HCl, filled to 500 ml with ddH2O 
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To 1 ml elution fraction add 50 µl 
 
NaN3  0.1% ( w/v) Merck, Darmstadt 
   
Dialysis buffer   
PBS   
 
GST fusion protein purification   
Beads   
Glutathione Sepharose 4B Beads Amersham, Freiburg  
  
Isopropyl-1-thio-β-D-galactopyranoside (IPTG) 1 mM Calbiochem, Darmstadt 
   
Lysis buffer    
Triton®X100  1% (v/v) Merck, Darmstadt 
PBS   
   
Elution buffer    
Glutathione (reduced)  10 mM Sigma 
Tris-buffer pH 8.0  50 mM  
   
Dialysis buffer   
PBS   
   
Protein detection 
Coomassie® protein assay reagent  Pierce, IL, USA 
   
Coomassie staining solution   
Methanol  410 ml Sigma-Aldrich, Munich  
Acetic acid 70 ml Merck, Darmstadt 
ddH2O 520 ml Braun, Melsungen 
Coomassie brillant blue G250 0.125 g Merck, Darmstadt 
Coomassie destaining solution   
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Methanol  410 ml Sigma-Aldrich, Munich  
Acetic acid 70 ml Merck, Darmstadt 
ddH2O 520 ml Braun, Melsungen 
   
Cell lysis    
Lysis bufffer-1%NP40   
Nonidet®P40 (NP40)  1% (v/v) Merck, Darmstadt 
Tris-buffer, pH 7.4 20 mM Merck, Darmstadt 
NaCl 150 mM Merck, Darmstadt 
EDTA  5 mM Merck, Darmstadt 
   
Inhibitors in lysis buffer (listed as final concentration) 
Aprotinin (APR) Inhibits serine proteases  2 µg/ml Sigma 
Leupeptin (LEU) Inhibits trypsin-like serine and cysteine 
proteases  
2 µg/ml Sigma 
Phenylmethyl sulfonyl 
Fluorid (PMSF) 
Irreversible inhibition of serine proteases 1 mM Sigma 
Pepstatin A Inhibits aspartic proteases 2 µg/ml Sigma 
Sodium orthovanadate 
(SOV) 
Inhibits ATPase, phosphatase and tyrosine 
phosphatase 
1 mM Merck 
EDTA Broad spectrum metalloproteinase inhibitor 1-5 mM Merck 
Sodium fluoride (SF) Enzyme inhibitor e.g. pyrimidine nucleoside 
monophosphate kinase 
10 mM Fluka 
Sodium pyrophosphate 
(SPP) 
Cdc2 kinase inhibitor 1 mM Sigma 
   
Sample buffer (3×)   
Sodium dodecyl sulfate (SDS) 6% (w/v) Calbiochem, Darmstadt 
Glycine 30% (v/v) Merck, Darmstadt 
Tris-buffer pH 6.8 200 mM Merck, Darmstadt 
Bromophenol blue 0.005% (w/v) Merck, Darmstadt 
β-Mercapthoethanol (β-ME) 2-5% (v/v) Merck, Darmstadt 
   
SDS-PAGE (Sodium Dodecyl Sulfate-Polyacrylamid Gel Electrophoresis)  
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Running gel (30 ml per gel, 6%-12%) 
30% Acrylamid/0.8% Bisacrylamid 6-12 ml Carl Roth, Karlsruhe  
Tris-buffer 1M pH 8.8 12.2 ml Merck, Darmstadt 
SDS 10% 300 µl Merck, Darmstadt 
ddH2O 6.7-12.7 ml Braun, Melsungen 
Ammonium peroxodisulfate (APS) 20% 100 µl Merck, Darmstadt 
N,N,N’,N’-Tetramethylendiamin (TEMED) 20 µl Merck, Darmstadt 
   
Stacking gel (10 ml per gel)   
30% Acrylamid/0,8% Bisacrylamid 1.67 ml Carl Roth, Karlsruhe  
Tris-buffer 1M pH 6.8 1.25 ml Merck, Darmstadt 
SDS 10% 100 µl Merck, Darmstadt 
ddH2O 7.03 ml Braun, Melsungen 
20% APS 50 µl Merck, Darmstadt 
TEMED 10 µl Merck, Darmstadt 
   
Electrophoresis buffer (10× stock solution) 
Tris 30.3 g Merck Darmstadt 
Glycine 144 g Merck Darmstadt 
SDS 1 g Calbiochem, Darmstadt 
ddH2O up to 1 liter Braun, Melsungen 
Adjusted to pH 8.2-8.3   
   
Protein-Molecular Weight Standards 
Precision Protein Standards  Bio-Rad, Munich 
Protein Marker Low Range  Bio-Rad, Munich 
   
Western blotting    
Transfer-buffer    
Tris 25 mM Merck, Darmstadt 
Glycine 192 mM Merck, Darmstadt 
Methanol 20% (v/v) Sigma-Aldrich, Munich 
SDS 0.015% (v/v) Merck, Darmstadt 
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Adjusted to pH8.0, stored at 4°C   
   
Protein staining on membrane   
Ponceau S solution 
(0.1% Ponceau S (w/v) in 5% acetic acid (v/v))  
Sigma, Munich 
   
Washing buffer    
I. Tris-buffered saline (TBS)   
Tris 10 mM Merck, Darmstadt 
NaCl 150 mM Merck, Darmstadt 
Adjusted to pH 7.5-8.0   
 
II. Tris-buffered saline containing Tween-20 (TBST) 
Tween® 20  0.05% Merck, Darmstadt 
TBS 
   
Blocking solution   
5% (w/v) BSA in TBST    
0.22 µm filtered   
   
Stripping solution   
Tris pH 6.8 62.5 mM Merck, Darmstadt 
β-ME 2% (v/v) Merck, Darmstadt 
SDS 6.9% (v/v) Merck, Darmstadt 
ddH2O  Braun, Melsungen 
 
ECL™ western blotting detection reagents Amersham, Freiburg 
 
 
In vitro kinase assay 
  
Kinase buffer   
HEPES  25 mM Merck, Darmstadt 
MgCl2 10 mM Merck, Darmstadt 
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Manganese chloride (MnCl2) 10 mM Merck, Darmstadt 
Adjusted to pH 7.2   
   
Phosphor-32( [γ−32P]ATP)  10 µCi Amersham, Freiburg 
 
3.1.12. Antibodies  
A list of antibodies used for various biochemical analyses is given in Table 3.1.3..      
1-5 µg antibodies were used for immunoprecipitation, 1:1500 to 1:7500 (in TBST) 
dilutions were used for western blotting analysis.  
 
Table 3.1.3. Antibodies used for biochemical analysis 
Antibody Isotope Used for Manufacturer 
I. primary antibodies 
α-FasL (NOK-1) IgG1amAb IP BD Pharmingen, Heidelberg 
α-FasL (G247-4) IgG1amAb IP/WB BD Pharmingen, Heidelberg 
α-pTyr (4G10) IgG2bmAb WB Upstate Biotechnology, Hamburg 
α-myc IgG1mAb WB Invitrogen, Karlsruhe 
α-myc IgG2amAb IP Cell Signaling, Frankfurt 
II. Secondary antibodies 
goat anti-mouse/HRP F(ab')2 WB Amersham, Freiburg  
goat anti-rabbit/HRP F(ab')2 WB Amersham, Freiburg  
Abbreviations: WB, Western Blot; IP, Immunoprecipitation; mAb, monoclonal antibody; HRP, 
horseradish peroxidase 
 
 
3.1.14. Other material 
Nitrocellulose-membrane Hybond™-C extra Amersham, Freiburg 
Filter paper Whatman 3MM Whatman, Maidstone, UK 
Disposable filter unit 0.2 µm Schleicher & Schuell, Dassel 
Disposable filter unit 0.45 µm Schleicher & Schuell, Dassel 
Sterile vacuum filter 0.2 µm Millipore, Eschborn  
Cellstar® TC flasks, plates (24 well) Greiner bio-one, Frickenhausen
Nunc® TC plates (96 F, 96 U, 12 well, 6 well) Nunc, Danmark 
Falcon® TC dishes (10 cm, 20 cm) Becton Dickison, France  
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Microcentrifuge tubes 1.5 ml Sarstedt, Nümbrecht 
Centrifuge tubes15 ml, 50 ml Sarstedt, Nümbrecht 
Pipettes Sarstedt, Nümbrecht 
Tips with filter Greiner bio-one, Frickenhausen
MicroAmp® reaction tubes  Applied biosystems, Darmstadt 
Parafilm American National Lab 
Cuvette for spectrophotometer Sarstedt, Nümbrecht 
Gene pulser cuvette, 0.4 cm Bio-Rad, Munich 
Coverslips, round, 18 mm  Herenz, Hamburg 
Lab-Tek II chambered coverslips Nunc, Danmark 
Microscope slides and coverslips Sarstedt, Nümbrecht 
Centricon®-30 concentrator 30,000 MWCO Amicon, MA, USA 
Slide-A Lyzer®  dialysis cassette 10,000 MWCO Pierce, IL, USA 
Hyperfilm™ ECL/MP Amersham, Freiburg 
 
3.1.15. Equipments  
CO2-humidified incubator  Heraeus, Osterrode  
Biosafety cabinet Heraeus, Osterrode 
Radioactive shelter  Amersham, Freiburg  
Centrifuge Type 5415C Eppendorf, Hamburg 
Centrifuge Type Biofuge 15R Heraeus, Osterrode 
Centrifuge Type Megafuge 1.0 Heraeus, Osterrode 
Centrifuge Type J2MC (Rotor JA-14, JA-20) Beckman, USA 
Vortex mixers Eppendorf, Hamburg 
Rocky Fröbel Labortechnik 
Rotator Heto, Danmark 
Minishaker-MS1 IKA-Labortechnik 
Waterbath GFL, Burgwedel 
Heatblock DB-2 und DB-3 Techne, Wertheim  
Pippette Eppendorf, Hamburg 
Pipetus® Arkus Pipetting Aid  Hirschmann, Eberstadt 
Hemacytometer Fischer, Frankfurt/M 
Dounce-homogenizier Braun, Melsungen 
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Standard chromatography column C10 Pharmacia Biotech, Sweden 
pH Meter Modell 537 WTW, Weilheim 
Smart-Spec™3000-spectrophotometer Bio-Rad, Munich 
Hypercassette™ Amersham, Freiburg 
Gel dryer Bio-Rad, Munich 
Power Pack 200/300/2000 Bio-Rad, Munich 
Electrophoresis chamber Protean® II Bio-Rad, Munich 
Western-Blot transfer tank Trans-Blot® Bio-Rad, Munich 
Film developing machine Agfa-Curix60 Agfa, Germany 
Digital imaging and microscopy with "gel imager" software INTAS, Göttingen 
Sonifier 250, Ultrasonics Branson, USA 
PE2400 thermocycler Perkin-Elmer, Langen 
GenePulser II, RF model  Bio-Rad, Munich 
Inverse light microscope Carl Zeiss, Jena  
Zeiss laser scanning microscope LSM 510 with software Carl Zeiss, Heiderburg 
FACScan with cellquest software Becton Dickinson 
β scintillation counter Inotech, Switzerland 
γ scintillation counter Inotech, Switzerland 
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3.2. Methods 
Cell biology  
3.2.1. Cell culture 
Jurkat, HUT78 and KFL-9 cells were grown in RPMI1640 medium with 5% (v/v) FBS. 
RBL2H3 cells were maintained in RPMI1640 medium with 10% (v/v) FBS. HaCaT, 
HeLa, MeWo, 293T and HEK 293 cells were cultured in DMEM medium with 10% (v/v) 
FBS. Media were supplemented with 1% (v/v) Penicillin/Streptomycin and to DMEM 
medium, additional 1% (v/v) L-Glutamine was added. For passaging adherent cells, 
0.05%/0.02% (w/v) Typsin-EDTA solution was used to detach the cells. 
Human T cell PHA blasts and T cell clones/lines were cultured in RPMI1640 with 10% 
(v/v) FBS, antibiotics supplemented with rIL-2 (10 U/ml). T cells were restimulated 
periodically (every 14 to 21 days) with irradiated PBMC (4000 rad) and EBV-
transformed lymphoblastoid cell lines (6000 rad) in the presence of PHA (0.5 µg/ml) 
and rIL-2 (10 U/ml). After three days, dead cells were removed by Ficoll gradient 
centrifugation and T cells were further cultured in the presence of rIL-2.  
Cells were grown in cell culture flasks or tissue culture (TC) plates at 37°C in a 
humidified atmosphere with 5% CO2. All of the cells were routinely verified to be free of 
mycoplasma contamination by using a PCR-based mycoplasma detection kit (Minerva 
BioLabs, Berlin). 
 
3.2.2. Isolation of cells 
Human peripheral blood mononuclear cells (PBMC) were isolated from buffy coat 
preparations from healthy donors by Ficoll gradient centrifugation and were separated 
into NK-, T- cells (E+) by rosetting with neuraminidase-treated sheep erythrocytes (E) 
and subsequent gradient centrifugation. CD4+- or CD8+- T cells were further isolated 
by e.g. negative selection using complement-mediated lysis. 
 
Isolation of PBMC and generation of PHA blasts 
Buffy coat preparations diluted 1:2 in PBS were laid over Ficoll-Hypaque (density 
1.077 g/ml) and centrifuged at 2000 rpm for 20 min without brake. PMBC at the 
interface were collected and washed twice before resuspended in RPMI1640 medium 
and 5% FBS.  
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To generate PHA blasts, 0.5 µg/ml PHA was added to freshly isolated PBMC for 3 
days. Afterwards, dead cells were removed by Ficoll gradient centrifugation and 10 
U/ml exogenous rIL-2 was added to the culture medium. The cells were used after 14-
21 days.  
 
Production of neuraminidase–treated sheep erythrocytes 
20 ml sheep red blood cells (SRBC, 1:2 (v/v) in Alsever solution) were diluted with 20 
ml PBS. Upon three times centrifugation at 2000 rpm for 5 min without brake and 
removing the supernatant and the lymphocyte interface, SRBC in the pellet were then 
resuspended in 20 ml RPMI1640 medium containing 10% FBS and 0.5 ml 
neuraminidase, incubated at 37°C for 30 min followed by three washes with PBS. The 
erythrocytes pellet was then diluted 1: 10 (v/v) in RPMI1640 medium containing 10% 
FBS to get 10% SRBC suspension. 
 
Rosette–formation and isolation of (E+)T cells 
20x106 PBMC resuspension and 1 ml of the SRBC suspension were gently mixed and 
submitted to a Ficoll density centrifugation. T cells were enriched in the pellet. SRBC 
were lysed by adding 0.5-1 ml ammonium chloride (NH4Cl) and incubation for 3-5 
minutes. After three washes with RPMI with 5% FBS, the (E+) T cells were 
resuspended in culture medium. 
 
Isolation of CD4+ and  CD8+ T cells 
40 µg/ml α-CD4 or α-CD8 and 6 µg/ml α-CD56 antibodies were added into 20x106/ml 
(E+)T cells and incubated for 30 min on ice. The cells were then washed and 
resuspended with RPMI1640. Freshly prepared complement was added at a ratio of 
1:4 (v/v) followed by incubation at 37°C for 60 min. After removing the dead cells by 
Ficoll gradient centrifugation, the cells were recovered and checked for surface 
expression of CD4 and CD8. Cells were then activated by TCR/CD3 stimulation with 
or without the engagement of FasL. Some CD8+ T cells were used to generate 
cytotoxic cell lines. 
 
Establishment of CD8+ T cell lines 
Freshly isolated CD8+ T cell were resuspended in RPMI1640 medium with 10% (v/v) 
AB serum and stimulated with irradiated EBV-transformed lymphoblastoid cells for 
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three days. The cells were then expanded in RPMI1640 medium with 10% (v/v) AB 
serum supplemented with 10 U/ml rIL-2 and restimulated in the same way every 14 
days. After the third stimulation, a chromium release assay was carried out to evaluate 
the cytolytic potential of the cell lines.  
 
3.2.3. Functional analysis of cells 
Chromium-51 (51Cr) release assay 
EBV-transformed lymphoblastoid cells were used as target cells: 1x106 (0.5 ml) target 
cells were labelled with 50 µCi (1.85 Mbq) 51Cr at 37°C for 60 min. After 3 washes with 
medium (RPMI1640 and 10% FBS), the cells were resuspended in 5 ml medium. Two 
cytotoxic CD8+ cell lines (CD8+-K and CD8+-L) were used as effector cells. The cells 
were washed and adjusted to 2x106/ml with medium and serial 1:2 dilutions were 
made. Starting with the lowest E/T ratio (3.125:1, 12,500 cells) and ending with the 
highest (50:1, 200,000 cells), 100 µl of cell suspension were seeded in triplicate into 
96-well U-bottom plates (96U TC plates). For each target, 6 wells were left for 
spontaneous release (SR) and 3 wells were left for maximal release (MR). 100 µl 
medium were added to the SR wells and 100 µl of detergent (10% TritonX-100) were 
added to the MR wells. After the effectors were seeded, 25 µl (4,000) labelled target 
cells were loaded into each well. The plates were then centrifuged for 3 minute at  
1000 rpm and incubated at 37°C for 4 hours. The supernatant was then harvested and 
the 51Cr release level was assessed in the γ-counter. The percentage of specific lysis 
was calculated as:  
experimental 51Cr release - spontaneous 51Cr release 
maximum 51Cr release - spontaneous 51Cr release 
X 100% 
 
Proliferation assay 
To determine effects of FasL-engagement on CD3/TCR-induced proliferation of PBMC 
or T cell blasts, wells of 96-well flat-bottomed tissue culture plates (96F TC plates) 
were coated or not for 2 hours at 37°C with 1.0 µg/ml OKT3 or 0.5 ng/ml 
staphylococcal enterotoxin (SE) superantigens without or with 25 µg/ml FasFc or      
20 µg/ml anti-FasL mAb 5G51 or 25 µg/ml IgG Fc control proteins as indicated. In 
some experiments, 5.0 µg/ml α-CD28 was coated together with OKT3. Pretreated TC 
plates were washed three times with PBS before different cell subpopulations were 
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plated at 50,000 per well in 200 µl culture medium. 10 U/ml rIL-2 was added where 
indicated. On day 3, cells were "pulsed" with 3H-thymidine (1 µCi/well) and cultured for 
additional 18 hours. Cells were harvested and 3H-thymidine incorporation was 
assessed in a β-counter. 
 
3.2.4. Cell transfection and selection 
Calcium phosphate precipitation 
293T cells were seeded and grown to 60-70% confluency. The calcium phosphate 
transfection reactions were set up by mixing the same volume of BES (2x) or HBS (2x) 
with 250mM CaCl2 containing vector DNA. The CaCl2 solution was slowly dropped into 
the agitated BES (2x) or HBS (2x) solution on a vortex at a speed of 800 rpm. The 
reactions remained at room temperature for 10 minutes then were added dropwise into 
the culture medium. The cells were cultured and used after 18-24 hours. For different 
tissue culture dishes or plates (TC dishes or plates), the cell number and the amount 
of vector DNA and volume of buffer were adjusted according to Table. 3.2.1. 
 
Table. 3.2.1. Cell number, vector DNA and buffer volume used in different TC dishes 
dish or plate 
cell number/ 
volume of medium 
amount of vector 
(1:2) 
volume of buffer 
(2xBES/2.5 M CaCl2) 
10 cm dish 5-6 x105/10 ml 5 µg: 1 µg 500 µl/50 µl 
20 cm dish 2.5-3x106/40 ml 20 µg: 6 µg 2 ml/200 µl 
6-well plate 1.2-1.5x105/2 ml 1 µg: 0.2 µg 100 µl/10 µl 
12-well plate 1.2 x105/2 ml 1 µg: 0.2 µg 100 µl/10 µl 
 
Electroporation  
Cells grown to 0.3-0.5x106/ml or 80% confluency were pelleted and washed three 
times with PBS. Cell density was adjusted according to Table. 3.2.2. with 
electroporation medium. 20 µg vector (1-2 µg/ml) alone or with 6 µg (1-2 µg/ml) 
second vector and 200 µl of cell suspension were placed in a gene pulser cuvette and 
mixed. The cells were then pulsed in a Gene Pulser II (RF model). The parameters 
were fixed at a frequency of 40 kHz, 5 pulses with 1 second individual time. The 
voltage (Vol.), modification rate (Mod.) and duration time (Dur.) per pulse were 
adjusted accordingly. Table 3.2.2. lists the settings used for different cells in the 
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experiments. After electroporation, cells were immediately transferred into pre-warmed 
complete medium and cell clusters were resuspended thoroughly. Cells were cultured 
for 24-48 hours before they were used for staining, protein purification or selected for 
stable transfectants. 
 
Table 3.2.2. Different settings for cells pulsed by Gene Pulser II (RF model) 
 Settings  cell 
type 
cell 
density 
Electroporation 
medium 
Culture medium 
Vol. (V) Mod. (%) Dur. (mSec) 
RBL2H3 10x106 RPMI RPMI+10%FBS 300 100 5 
HeLa 10x106 RPMI DMEM+10%FBS 240 50 5 
Jurkat 20x106 RPMI RPMI+10%FBS 370 100 7 
HEK 100x106 FreeStyleTM  293T expression medium 300 100 5 
 
Selection of stable Jurkat FasL transfectants 
4 x106 Jurkat cells (JM301 or J16Rapo) were transfected with 20 µg FasLpEFBOS 
and 6 µg hygromycin-resistant vector by electroporation. 24 hours post transfection, 
the dead cells were removed by Ficoll density centrifugation. The living cells were 
counted, resuspended with culture medium and seeded into 96U TC plates under 
limiting dilution conditions starting from 10,000 cells per well at the volume of 100 µl. 
Cells were cultured for another 24 hours before 100 µl culture medium containing    
600 µg/ml (2x concentrated) hygromycin B were added. Every 4 days, half of the 
medium was carefully removed and replaced with fresh medium containing 300 µl/ml 
hygromycin B. Cells were kept in culture until some cell clusters were visible under an 
inverse light microscope (around 20 days). Clusters were selected and transferred to 
24 well plates for further expansion. The FasL expression was checked by FACS 
analysis, RT-PCR and western blotting. FasL expressing cells were then subcloned. 
The J16Rapo FasL stable transfectants were named as JFL while the JM301 FasL 
stable transfectants were named JMFL. 
 
3.2.5. FACS analysis 
Surface antigen staining  
50,000-100,000 cells were stained in 96-well V-bottom (96V) TC plates according to a 
standard FACS staining procedure: Cells were pelleted by centrifugation at 1000 rpm 
for 4 minutes at 4°C and washed once by FACS wash buffer. For staining, cells were 
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incubated with FITC- or/and PE-conjugated antibody for 20-30 min on ice. The cells 
were then washed 3 times before they were fixed with 100 µl 1% PFA and transferred 
into a FACS analysis tube. Alternatively, gam-PE was used to detect unlabelled 
primary antibodies and SA-PE or Avidin-FITC was used to analyze biotinylated 
antibodies. The samples were analyzed in a flow cytometer (FACScan) with cellquest 
software. In some cases, the reading value of geometric log mean fluorescence of the 
stained samples were batched and transferred to windows-excel for further analysis. 
 
DNA staining for cell cycle analysis 
A propidium iodide (PI)-based nuclear DNA staining indicated cell cycle phase 
analysis was used as one of the parameters to measure lymphocyte activation and 
proliferation: 0.5-1x106 cells were transferred into a 15 ml centrifuge tube, washed, 
resuspended in wash buffer and fixed by dropping of 1ml of 100% ethanol into the 
agitated cell resuspension. Cells were fixed at room temperature for 30 minutes or 4°C 
overnight. Fixed cells were pelleted by short spin (5 minutes) at high speed (3000 rpm) 
and resuspended with 100 µl wash buffer plus 4 µl RNase (1 mg/ml) for 30 minutes 
followed by adding 100 µl 50 µg/ml PI solution. Samples were then analyzed in the 
flow cytometer.  
 
PI staining of dead cells  
Being pelleted and washed once with FACS washing buffer, cells were resuspended 
with 2.5 µg/ml PI solution and analyzed immediately in flow cytometer. Propidium 
iodide (PI) intercalates into double-stranded nucleic acids. It is excluded by viable cells 
but can penetrate cell membranes of dying or dead cells. 
 
Molecular biology  
3.2.6. Reverse transcription-polymerase chain reaction-based cloning 
Standard reverse transcription polymerase chain reaction (RT-PCR)-based cloning 
methods were used for most constructs. cDNA derived from either human Jurkat T 
cells or re-stimulated T cell PHA blasts served as templates. The primers were 
designed according to the published sequences with adding flanking restriction sites 
for unidirectional insertion. 
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RNA extraction and RT-PCR  
1-2x106 cells (restimulated T cell blasts, HUT78 cells) were washed in PBS, pelleted 
and used for RNA extraction with RNeasy® Mini Kit following the manufacturer’s 
instruction. RNA was eluted in ddH2O and the concentration was determined in a 
spectrophotometer. 500 ng RNA was used for the reverse transcription reaction. 4 µl 
of cDNA were used for GAPDH PCR by GeneAmp® RNA PCR kit (Applied 
Biosystems, Darmstadt). For cloning PCR, „proofreading“ (Pfu) DNA polymerase was 
used. The set up of reactions and the PCR programs used are listed in Table 3.2.3. 
The production was checked by loading 10% of individual PCR products on a 1% 
agarose gel containing 0.5 µg/ml EB, separated by electrophoresis and visualized with 
ultraviolet (UV) light. 
 
Table 3.2.3. PCR mixes and programs for RT-PCR 
Reactions 
RT Regular PCR Cloning PCR 
MgCl2 (25 mM) 4 µl MgCl2 (25 mM) 3 µl PCR-buffer (10x) 
PCR-buffer (10x) 2 µl PCR-buffer (10x) 5 µl dNTPs (10 mM each) 
dNTPs (10 mM each) 1 µl (each) dNTPs (10 mM each) 1 µl (each) Primers (10 pmol/µl each) 
5 µl 
1 µl (each) 
2.5 µl (each) 
RNase Inhibitor (20 U/µl) 1 µl ddH2O 28.5 µl Pfu DNA polymearse 0.5 µl 
MuLV-RT (50 U/µl) 1µl AmpliTaq (5 U/µl) 0.5 µl cDNA 4 µl 
Oligo d(T)16Primer (50 µM) 1 µl Primers (10 pmol/µl each) 2.5 µl (each) ddH2O 31.5 µl 
RNA 500 ng cDNA 4 µl   
Program for RT: 42°C, 30sec; 99°C, 5min; 4°C, ∞ 
Programs for PCR 
Step Regular PCR Cloning PCR 
Initial denaturation  94°C, 5 min  94°C, 5 min  
Denaturation 94°C, 30 sec 94°C, 50 sec 
Annealing 58°C, 30 sec Tm, 50 sec 
extension 
Cycles 
72°C, 40-60 sec 
x25-35 
72°C, 1-2 min/Kb 
x35 
Final extension  72°C, 7-10 min  72°C, 7-10 min  
Soak  4°C, ∞  4°C, ∞  
 
Restriction endonuclease digestion 
PCR products were purified and eluted in 30 µl ddH2O by using QIAquick PCR 
purification kit. According to the flanking restriction sites included within the respective 
primers, the restriction endonuclease (RE) reaction were set up by adding 5-10 U 
RE(s) with appropriate buffer to 30 µl PCR products or 5 µg target cloning vector in   
50 µl volume and incubated at 37°C overnight. 
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Extraction of DNA fragments from agarose gels and ligation 
The whole reactions were loaded on a 1% agarose gel. After electrophoresis, the 
stained DNA fragments were excised from the gel under UV light followed by 
extraction and purification by using QIAquick Gel Extraction Kit. 2 µl of recovered DNA 
were checked by electrophoresis. A standard DNA ladder with indicated concentration 
was used to estimate the amount of DNA. 50-200 ng insert DNA and 50 ng vector 
DNA were ligated by 1 µl T4 DNA ligase with T4 DNA ligase buffer in a volume of 20 µl. 
The ligation reactions were incubated at 16°C overnight. 
 
TA cloning  
In some cases, addition of 3’-overhangs was done post amplification before the PCR 
products were cloned into a PCR 2.1 TOPO TA Cloning vector. Briefly, after 
amplification with a Pfu polymerase, vials were placed on ice and supplemented with  
1 unit of Taq polymerase followed by incubation at 72°C for 8-10 minutes. The TOPO 
cloning reactions were set up by gently mixing 4 µl PCR product, 1 µl salt solution with 
1 µl Topo vector and incubated at room temperature for 5-30 minutes. 
 
Transformation  
2 µl of each ligation reaction was transformed into "Subcloning Efficiency™ DH5 ™ 
Competent Cells" according to the manufacturer’s protocol. In brief, competent cells 
were thawed on ice and divided into prechilled 1.5 ml centrifuge tubes (50 µl per vial). 
2 µl of ligation reaction was pipetted directly into the cells and incubated on ice for 30 
minutes. Cells were then "heat shocked" for exactly 25 seconds in a 37°C heatblock 
followed by 2 minutes incubation on ice. 450 µl prewarmed LB medium was added to 
each vial and the cells were incubated by shaking horizontally at 300 rpm, 37°C for 
exactly 1 hour before spread onto LB agar plates containing antibiotics (50 µg/ml 
ampicillin or 30 µg/ml kanamycin) and cultured in a 37°C incubator for 18-24 hours 
until the transformed bacteria expressing the resistance gene were visible as colonies. 
3-6 colonies were selected and cultured in LB medium with antibiotic at 37°C 
overnight. Plasmid DNA was extracted with QIAGEN® plasmid Mini Kit and used for 
further analysis.  
 
 
 
PART 3 -43- MATERIALS AND METHODS 
 
Positive colony selection 
Positive colonies were selected by checking the restriction endonuclease cleavage 
sites of the plasmid DNA and proved by sequencing. The Big-dye™ terminal 
sequencing kit was used for sequencing PCR and the primers used for sequencing 
were T7 promoter sequencing primer, pGEX 5’ primer, pGEX 3’ primer and the same 
primer used for PCR. Table 3.2.4. lists the set up of reactions and programs for 
sequencing PCR. After removing the dye with DyeEx spin Kit, the PCR products were 
sent for in house sequencing. The data were analyzed with blast software from NCBI. 
 
Table 3.2.4. PCR mix and program for sequencing PCR 
Reaction Program 
DNA  0.4 µg Denaturation     96°C, 10 sec 
Big-Dye terminator 4 µl Annealing          50°C, 5 sec 
Primer 10 pmol/µl 1 µl Extension          60°C, 4 min 
25 cycles 
ddH2O  up to 20 µl Soak                  4°C, ∞  
 
3.2.7. Subcloning  
Some constructs were obtained by cutting DNA fragments from a previously 
constructed vector with specific restriction endonucleases which allowed in-frame     
re-ligation into another opened vector (as summarized in Table 3.2.5.). In some cases, 
a blunt end ligation strategy was used.  
 
Table 3.2.5. Constructs obtained from subcloning 
Insert  From RE sites Target vector RE sites Ligation  
FasL  pEYFP C1 EcoRI / BamHI  pEGFP C1 EcoRI / BamHI cohesive-ended  
FasL pcDNA3.1 EcoRI, 5’ fill in pEFBOS XbaI blunt-ended 
SH3P12  PCR2.1TOPO HindIII / EcoRI  PCDNA3.1myc  HindIII / EcoRI  cohesive-ended 
BAP2-β PCR2.1TOPO BamHI / EcoRI PCDNA3.1myc BamHI / EcoRI  cohesive-ended 
Nck1 all SH3s mut pcDNA3/myc BamHI / EcoRI PEGX2T BamHI / EcoRI cohesive-ended 
SH3P12 encoding FLAF2; BAP2-β encoding FLAF3; mut: mutated  
 
5’ modifications of insert and vector for blunt-ended ligation 
In order to produce blunt-ended insert DNA, the Klenow fragment of DNA polymerase I 
was used to fill in the 5’ overhang of digested DNA. After inactivating the RE reaction 
at 72°C for 15 minutes, 20 U Klenow (8 U/µl) and 1 µl of 1 mM dNTPs were added into 
the reactions and incubated for 15 min at room temperature. Meanwhile, in order to 
prevent self ligation, alkaline phosphatase (AP) was used to remove the 5’ phosphate 
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group from blunt-end opened vectors by twice heating the reactions to 56°C for 10 
minutes followed by supplementing with 5.5 µl AP buffer and 1 µl (140 U/µl) AP and 
incubation at 37°C for 30 minutes. The modified insert and vector reactions were then 
loaded on 1% agarose gel separately. After electrophoresis, the respective DNA 
fragments were extracted from the gel and processed for ligation. 
 
Biochemistry  
3.2.8. Purification of FasFc fusion protein 
The FasFc fusion protein was produced from transiently transfected HEK 293 cells 
and purified by affinity chromatography on a Protein A column. 72 hours after 
transfection, culture supernatant was collected, filtered and the pH was adjusted to   
pH 7.0. The medium was then passed over a protein A sepharose CL-4B column 
which was balanced with binding buffer (start buffer) followed by extensive washes 
with start buffer again. The bound protein was eluted from the column to collection 
tubes in a fraction collector. The collection module was set to 30 drops per fraction.   
50 µl of neutralizing buffer was added into each collection tubes. The protein 
concentration in fractions was determined by Coomassie® Protein Assay Reagent in 
comparison to an albumin standard and read in a Smart-Spec™3000 
spectrophotometer at the wavelength of 595 nm. The fractions which contained most 
protein were then pooled, concentrated by Centricon®-30 concentrator (30,000 
MWCO), and dialyzed in Slide-A Lyzer®  dialysis cassette (10,000 MWCO) against 
PBS. The fusion protein was separated by SDS-PAGE on a 10% gel and stained in gel 
with coomassie blue solution. The bioactivity was tested by inhibition of Fas-mediated 
lysis on Jurkat cells or AICD of T cell clones. After usage, the protein A sepharose  
CL-4B column was cleaned by 5 beds of elution buffer followed by at least 20 beds 
start buffer containing 0.01% NaN3, closed and stored at 4°C. 
 
3.2.9. GST fusion protein expression and purification 
GST fusion proteins were derived by induced expression with IPTG from transformed 
E.coli (DH5α) followed by affinity binding to glutathione beads as follows: 
For small scale GST-fusion protein expression, bacteria (DH5α) were cultured in 3 ml 
medium (LB medium with 50 µg/ml Amplicillin) in a horizontally shaking incubator at 
300 rpm, 37°C overnight. The next day, 500 µl cell resuspension were 1:10 diluted into 
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fresh medium and cultured for 2 hours before IPTG was added to a final concentration 
of 1.0 mM. Cells were allowed to grow for an additional 5 hours to produce protein 
before they were pelleted and washed once in PBS. Upon resuspension in 900 µl 
PBS, bacteria were transferred into a 1.5 ml centrifuge tube. Cells were kept on ice 
throughout the procedure and were lysed by two cycles of sonication for 5 seconds 
each followed by adding 100 µl TritonX-100 (1% final concentration). The cell lysates 
remained on ice for 20 minutes and were then centrifuged at 140,000 rpm, 4°C for    
10 minutes. The fusion protein in the supernatant was isolated by binding to 
glutathione sepharose 4B beads as follows: 60 µl 50% glutathione sepharose 4B 
beads (in PBS) were incubated with cell lysates for 30 minutes at 4°C on a rotator. 
After quick spin centrifugation, beads were washed extensively with PBS for at least 
three times. The beads-bound fusion protein were ready to use.  
For large scale GST-fusion protein expression, 100 ml LB-Amp medium were used for 
the initial culture. The cells were 1:10 diluted into 300 ml fresh medium for 2 hours 
before adding IPTG for 5 hours. Afterwards the cells were pelleted, washed and lysed 
by sonication in 27 ml PBS, 3x20 seconds followed by addition of 3 ml 10% Triton X-
100. After centrifugation, 1 ml of 50% glutathione sepharose 4B beads (in PBS) was 
used to precipitate the fusion protein during 20 minutes of rotation at room 
temperature. After several washes, the protein concentration was determined and the 
purity was visualized by electrophoresis. In some cases, the proteins were further 
eluted by three cycles of incubation with glutathione elution buffer for 5 minutes each 
at room temperature on a rotator. The proteins were collected, concentrated, dialysed 
against PBS and stored at -80°C.  
 
3.2.10. Protein “pull down” assays  
For protein “pull down” assays with GST fusion protein, lysates from 10-20x106 cells 
were used. The cells were pelleted, washed with PBS and lysed in 1 ml of 1% NP40 
buffer with protease and phosphatase inhibitors followed by 10 times homogenization 
with a dounce-homogenizier. Lysates remained on ice for 10 minutes before 
centrifugation at 4°C and 14000 rpm for 10 minutes. Supernatants were then 
transferred into fresh tubes and incubated for 2 hours rotating at 4°C with 20-50 µg of 
indicated GST fusion protein. 50 µl of a 50% slurry of glutathione sepharose 4B beads 
were added directly to the samples. The beads were then pelleted, washed thrice in 
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cold PBS, boiled in sample buffer containing ß-ME and separated by SDS-PAGE 
followed by western blotting. 
 
3.2.11. Immunoprecipitation  
For co-immunoprecipitation, 3x106 293T cells were collected and lysed in 1 ml          
1% NP40 buffer 24 hours after transfection. Lysates remained on ice for 10 minutes 
before centrifugation at 4°C and 14000 rpm for 10 minutes. Supernatants were divided 
equally and incubated for 2 hours rotating at 4°C with 2-5 µg of the respective antibody 
and 50 µl of a 50% slurry of Protein A sepharose CL4B beads. The beads were then 
pelleted, washed thrice in cold lysis buffer, boiled in sample buffer containing ß-ME 
and separated by SDS-PAGE followed by western blotting. 
 
3.2.12. Cell stimulation and anti-phosphotyrosine western blotting  
To analyze potential effects of FasL engagement on TCR/CD3-induced tyrosine 
phosphorylation, cells were pre-incubated with or without FasFc (50 µg/ml) crosslinked 
with 10 µg/ml anti-human IgG Fc or 20 µg/ml anti-FasL mAb 5G51 crosslinked with     
5 µg/ml rabbit anti-mouse IgG. Cells were then incubated at 37°C for 30-120 minutes 
in the presence or absence of the indicated reagents before aliquots of 1.5-2х106 cells 
were exposed to OKT3 at 10 µg/ml for the indicated time periods. Stimulation was 
stopped by adding 1 ml ice-cold PBS, quick spin centrifugation, aspiration of the 
PBS/antibody supernatant and immediate lysis in 30 µl of 1% NP40 lysis buffer with 
protease and phosphatase inhibitors. Lysates remained on ice for 15-30 minutes 
before centrifugation at 4°C and 14000 rpm for 7 minutes. Supernatants were then 
transferred into fresh tubes, boiled in an equal of sample buffer containing ß-ME and 
were separated by SDS-PAGE followed by western blotting procedure.  
 
3.2.13. SDS-PAGE and Western blot 
The cleaned glass plates were assembled and filled in with standard running gel 
followed by stacking gel. The gel apparatus were assembled and the gels were run 
either at 60 voltage overnight or at 200 voltage within 6 hours with cooling. The gels 
were transferred right after the electrophoresis. The transfer sandwich was assembled 
from cathode to anode with sponge, 2 pieces of Whatman 3MM-paper, gel, 
nitrocellulose, 2 pieces of Whatman 3MM-paper, sponge in a plastic cassette. The 
cassette was placed into the transfer tank and the protein transfer was performed at 
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0.8 A, 4°C for 2 hours or 0.15 A overnight. The efficiency and quality of transfer was 
monitored by staining the membrane with Ponceau S solution. After the washes with 
TBST to remove the staining from proteins, the blots were blocked with 5% BSA 
blocking solution for 1 hour and incubated with primary antibody diluted in TBST for 1 
hour followed by HRP-linked secondary antibodies diluted in TBST for 45-60 minutes 
at room temperature. Between each step, the blots were washed trice with TBST for 
10 minutes. After rinsing in water, ECL developing solutions were prepared and added 
to the blot for one minute. Hyperfilm™ ECL films were used for visualizing emitted 
chemiluminescence.  
 
3.2.14. In vitro kinase assay 
The full length FasL cytosolic region (FasLcyto), the N-terminal part (FasLcyto1) and 
the membrane-proximal portion (FasLcyto2) expressed as GST fusion proteins, kept 
on glutathione sepharose beads (Fig. 3.2.1) were used as substrates for in vitro 
casein kinase assay: 50 µg fusion protein combined to beads were used for each 
reaction. After the beads had been 
washed extensively in kinase 
buffer and dried by aspirating all 
buffer with a 27G needle, the 
kinase reactions were carried out 
by incubating the dry beads with 
30 µl kinase buffer in the absence 
or presents of 100 U or 500 U 
recombinant casein kinase1 
together with 10 µCi [32P]ATP for 
20 minutes at room temperature. 
The reaction was stopped by 
adding 60 µl 2× sample buffer containing ß-ME and heating to 100°C for 5 minutes. 
Samples were separated by SDS-PAGE and the gel was stained by coomassie blue 
and dried in a gel dryer. The autoradiography was performed by using Hyperfilm™ MP 
films.  
 
 
Fig.3.2.1. FasL cytosolic GST fusion protein constructs.
FasLcyto contains the complete cytoplasmic tail of FasL,
consisting of 80 aa (36.5 kDa); FasLcyto1 contains the N-
terminal region of 29 aa (33.5 kDa) and FasLcyto2 contains
the membrane proximal proline-rich stretch with 53 aa (31
kDa). Importantly, FasLcyto and FasLcyto1 contain the
putative CK1 motif SSASS.  
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Immunostaining and confocal microscopy 
3.2.15. Coverslips and cell preparation 
Cleaning and pretreatment of the coverslips 
Coverslips were cleaned in 37.5% HCl for 15 min, washed in ddH2O followed by 70% 
ethanol and sterilized by dry heating at 180°C for 2 hours. 
 
Pretreatment of the coverslips 
Coverslips were coated with 50-100 µg/ml poly-L-lysine for 30 min at room 
temperature. Afterwards, the liquid was removed and the coverslips were washed with 
PBS. In some experiments, 10 µg/ml OKT3 or 0.5 ng/ml SEA diluted in PBS were 
loaded on poly-L-lysine pretreated coverslips at 37°C for 2 hours.  
 
Cell preparation  
For adherent cells, 1.2-1.5x105 cells were grown on coverslips in  12 well plates for  
24-28 hours before they were used for transfection or co-culture experiments.  
For cells in suspension, 1-1.5х106 cells were washed and resuspended in 300 µl PBS 
and loaded on poly-L-lysine pretreated coverslips at 4°C for 15 minutes. Cell adhesion 
was controlled by light microscopy. Non-adherent cells were removed carefully and the 
samples were ready for fixation. 
 
Stimulation of the cells 
1-1.5х106 cells were cultured on pretreated coverslips in 300 µl of medium without 
FBS for the indicated time intervals. Stimulation was stopped by removing the non-
adherent cells carefully, washing the sample once with PBS followed by fixation. 
In experiments where cells were stimulated by soluble agents, the cells were cultured 
in wells containing pretreated coverslips and stimulated by adding the stimuli directly 
to the culture medium to a final concentration of 10 ng/ml TPA and 500 ng/ml 
ionomycin. To determine kinetics of the stimulations, the experiments were designed 
to allow simultaneous fixation and treatment of all samples. To this end, cells were 
quickly fixed by –20°C methanol for 5 minutes.  
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Pretreatment of the cells 
Cells were cultured in medium supplemented with respective inhibitors or dyes for the 
indicated time periods (Lysotracker Red DND-99, 100 nM, 1 hour; Latrunculin A, 5 nM, 
30 minutes; Cytochalasin D, 10 µM, 30 minutes) before they were washed, 
resuspended in PBS and loaded on coverslips.  
 
Co-culture of the T cells and B cells 
T cells and target B cells were mixed at a ratio of 2:1 and cultured for 20 minutes 
before they were carefully moved onto poly-L-lysine pretreated coverslips for 15 min at 
4°C. After removing non-adherent cells, the samples were washed once with PBS and 
processed for fixation.  
 
3.2.16. Fixation 
Cells were fixed by –20°C methanol for 5 minutes or alternatively, by a pH-
shift/formaldehyde fixation method. To this end, cells were washed once with PBS, 
fixed with 3% PFA in PEM buffer for 5 min followed by 3% PFA in borate buffer for 10 
minutes and permeabilized in 1% Trition-X100 for 15 min. After rinsing 3 times with 
PBS, the samples were treated twice with freshly dissolved 1 mg/ml borohydride 
(NaBH4) for 10 minutes each to reduce the unreacted aldehydes followed by 3 rinses 
with PBS. The samples were then ready for staining. 
 
3.2.17. Staining 
The samples were blocked with 0.2%BSA in PBST for one hour followed by incubation 
with appropriate primary and fluorescent-conjugated secondary antibodies or 
reagents. The incubation periods were 1 hour at room temperature or overnight at 4°C 
for the primary antibodies and 50 minutes at room temperature for the secondary 
reagents. Samples were washed 3 times in PBS between each step. In double stained 
samples, one antibody and one colour-tagged vector were used while in triple-stained 
samples, two different species of primary antibodies and one colour-tagged vector 
were used. After being mounted with anti-fate mounting medium and sealed by nail 
polish, the stained samples were processed for analysis and kept at 4°C in dark. 
 
 
PART 3 -50- MATERIALS AND METHODS 
 
3.2.18. Laser scan confocal microscopy  
The stained samples were analysed under the laser scanning microscope LSM510 
with software. The emission and excitation wavelengths used for different dyes or 
vectors are listed in Table 3.2.6. Laser 488, 543 
and 633 were set for two- or three-fluorescence 
imaging as shown in Fig.3.2.2. (adapted from 
Bio-Rad fluorescence database). 
 
Table 3.2.6. Excitation (Ex) and emission (Em) 
wavelengths (nm) for different dyes or vectors 
 
Fluorochrome Ex(max) Em (max) 
Alexa 488 492 520 
Alexa 546 557 572 
CY5 649 666 
DsRed 556 583 
EGFP 498 516 
EYFP 520 532 
Rhodamine 550 573 
Lysotracker Red DND-99 577 590 
 
3.2.19. Observation of living cells and video recording 
To visualize the contact of γδ T cells (EP3) and tumor cells. 50,000 MeWo cells were 
grown on Lab-TekII chambered coverslips for 24 hours. 1x106 EP3 cells were cultured 
in medium containing 50 nM Lysotracker Red DND-99 for 1 hour followed by 2 times 
washes with medium. Right before the EP3 cells were loaded to the MeWo cells,      
200 nM BrHPP was added. Medium alone with 200 nM BrHPP was used as control. 
The chamber was then plated on a temperature-controlled specimen stage of the 
microscope and the culture medium of MeWo cells was replaced by either the 1 ml 
Lysotracker Red loaded EP3 cell resuspension or the control medium. Sequential 
confocal images were acquired every 1 minute up to 2 hours with the start point the 
MeWo cells were focused. Laser 546 was used to monitor the lysosomal compartment 
stained with lysotracker Red in EP3 cells and a normal transmission light was used to 
show the cell morphology changes. After 2 hours, the cells in the control chamber 
were observed for comparison. 
Fig. 3.2.2. The distribution of Em
wavelengths excited from different
lasers. The curves from the left to right
indicate EGFP-(Em), Rhodamine-(Em),
CY5-(Em) and the lines from the left to
the right indicate Laser-543 and Laser-
633. 
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4. Results  
4.1. Reverse signal transduction of FasL in human T cells 
Over the past few years, it became obvious that several members of the TNF 
superfamily exert a bi-directional signaling capacity (see for a review137). However, in 
most cases the underlying biochemical mechanisms remained unclear. For FasL, the 
most convincing data stem from experiments done with Fas (lpr, lprcg) or FasL (gld) 
mutant mice. Cells from those mice are in principle resistant to Fas-FasL induced cell 
death and develop lymphoaccumulation and splenomegaly and autoimmune 
diseases63,64. Utilizing FasL or Fas defect mutant mice, several groups demonstrated 
that the expression of functional FasL is required for "normal" activation of mature 
CD4+ or antigen-specific CD8+ T cells68-71. Besides, FasL-to-TCR-crosstalk seems to 
be involved in positive selection of thymocytes depending on the antigen affinity during 
the selection process72. For human cells, FasL signaling has not been convincingly 
demonstrated. Most effects of an intervention into Fas/FasL system were claimed to 
involve Fas rather than FasL signal transduction138. One aim of the present study was 
to demonstrate an influence of FasL stimulation on the outcome of TCR/CD3-triggered 
activation or effector function. 
 
4.1.1. Generation and functionality of a FasFc fusion protein 
In order to specifically engage FasL, we constructed a FasFc fusion protein. The 
construct was designed to encode the extracellular domain of human Fas (aa 1-173) 
and the Fc portion of human IgG1 (Fig. 4.1.1A). The protein was purified from 
supernatant of HEK 293 transfectants by affinity chromatography. On 10% gels, the 
fusion protein migrated at around 60 kDa. The purified FasFc was tested by analyzing 
the inhibitory effect on activation-induced cell death (AICD) in a staphylococcal 
enterotoxin superantigen A (SEA)-reactive T cell clone. To this end, clone cells were 
incubated with SEA or TPA/ionomycin in the presence or absence of FasFc (25 µg/ml) 
or anti-FasL mAb 5G51 (20 µg/ml). As shown in Fig. 4.1.1B, AICD induced by SEA 
and TPA/ionomycin could be blocked in part by FasFc as well as the anti-FasL 
antibody 5G51. 
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4.1.2. Crosslinked but not soluble FasL inhibits proliferation of PBMC 
Since the bi-directional modulation of signaling pathways often requires crosslinking of 
the receptors involved, the following experiments were designed to mimic crosslinking 
of the TCR/CD3 complex and/or FasL. To this end, wells of 96-well flat-bottom tissue 
culture plates (96F TC plates) were pre-coated with OKT3 mAb or staphylococcal 
enterotoxin (SE) superantigen alone or together with FasFc fusion protein. Under 
conditions where we used low concentrations of the respective TCR/CD3 stimulus, the 
presence of plate-bound FasFc fusion protein had a quite dramatic effect. As shown in 
Fig. 4.1.2A and B, OKT3- (A) or superantigen- (B) induced stimulation of proliferation 
of freshly isolated PBMC from all tested donors was inhibited by at least 64% (A, 
donor 1) and at most 92% (A, donor 3). In contrast, when soluble FasFc fusion protein 
was added to the medium of cells that were stimulated by plate-bound TCR/CD3 
agonists, only a very mild inhibition of thymidine uptake was detectable (Fig. 4.1.2C, 
5.3% for OKT3 and 15% for superantigen). It is important to note that the Fas but not 
the Fc part of the fusion protein displayed the inhibitory function. As shown in Fig. 
4.1.3A, the Fc fragment of human IgG had only little or no effect on the CD3- or 
Fig. 4.1.1. FasFc fusion protein and anti-FasL mAb 5G51 block AICD of CD4+ clone cells. 
(A) Generation and purification of FasFc: the vector for FasFc was designed that at the protein level
the extracellular domain of human Fas (aa 1-173) was fused to the Fc portion of human IgG1. The
chimeric protein migrates at 60 kDa in denaturing SDS-PAGE. (B) Inhibition of AICD: CD4+ clone cells
were cultured in medium alone or in the presence of staphylococcal enterotoxin superantigen A (SEA,
0.5 ng/ml) or TPA/ionomycin (10 and 500 ng/ml, respectively) in the absence or presence of 20 µg/ml
anti-FasL mAb 5G51 or 50 µg/ml FasFc. After 16 hours, cells were harvested and stained with
propidium iodide (PI) followed by FACS analysis. The cell viability was determined. 
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superantigen-induced proliferation of PBMC whereas the FasFc fusion protein reduced 
the thymidine uptake by 92% in the case of OKT3 and by 77% in the case of 
superantigen.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.1.3. Crosslinked FasL inhibits proliferation of T cell blasts in the absence of 
exogenously added rIL-2  
We also observed an inhibitory effect of FasL crosslinking on the proliferation of T cell 
blasts in the absence of exogenously added IL-2. Although T cell blasts at that stage 
showed only a limited increase in TCR/CD3-induced proliferation (probably due to the 
lack of growth factor), the reduction in the presence of plate-bound FasFc but not in 
the presence of the Fc control fragment was quite obvious (Fig. 4.1.3B).  
Fig. 4.1.2. Crosslinked but not soluble FasL inhibits proliferation of PBMC. PBMC from 3
different donors were cultured for 3 days in 96F TC plates coated with 1 µg/ml anti-CD3 mAb OKT3
(A,C) or 0.5 ng/ml staphylococcal enterotoxin (SE) superantigen (B,C). FasFc (25 µg/ml) was either
also coated on the plates (A, B) or added as a soluble factor to the culture medium (C). Proliferation
was determined by 3H-thymidine incorporation. Data are represented as mean values of triplicate
wells. 
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To further analyze a possible involvement of IL-2 and the activation state in the FasL-
sensitivity of T cell populations, we added exogenous growth factor. Note that the 
inhibition could also be achieved when plate-bound anti-FasL antibody instead of 
FasFc was used to crosslink FasL (Fig. 4.1.4). Interestingly, as demonstrated in      
Fig. 4.1.4, there was a clear bias in the IL-2 effect between freshly isolated PBMC (A) 
and T cell blasts (B). Whereas in PBMC, addition of exogenous recombinant IL-2   
(rIL-2) had only little effect on the FasFc- or anti-FasL-dependent reduction of 
proliferation, in T cell blasts the inhibitory effect of both reagents was completely 
overcome by adding rIL-2. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.1.3. FasL signaling
inhibits proliferation of
PBMC and T cell blasts.
PBMC (A) or T cell blasts (B)
were cultured for 3 days in
wells coated with 1 µg/ml anti-
CD3 mAb OKT3 or 0.5 ng/ml
staphylococcal enterotoxin
(SE) superantigen with or
without 25 µg/ml FasFc or
human IgGFc control protein.
Proliferation was determined
by 3H-thymidine incorporation.
Data represent mean values of
triplicate cultures.  
Fig. 4.1.4. rIL-2 counteracts
FasL effects in T cell blasts
but not in PBMC. PBMC (A)
or T cell blasts (B) were
cultured for 3 days in culture
plates coated with 1.0 µg/ml
anti-CD3 mAb OKT3 without or
with 25 µg/ml FasFc or 20
µg/ml anti-FasL mAb 5G51 in
the absence or presence of
10 U/ml rIL-2. Data for 3H-
thymidine uptake are given as
mean value of triplicate
cultures. 
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4.1.4. FasL-engagement inhibits proliferation of freshly isolated human 
peripheral T cells  
Next we examined effects of FasL-engagement on different freshly isolated T cell 
populations. T cells were purified by E-rosette formation with sheep red blood cells 
(E+). CD4+ or CD8+ subsets were further enriched by negative selection using 
complement mediated lysis. The purity of CD4+ or CD8+ T cells was more than 90% 
(Fig. 4.1.5). 
 
 
 
 
 
 
 
 
 
 
In all experiments, we consistently found that anti-CD3 or anti-CD3 and anti-CD28 
triggered proliferation of E+, CD4+ and CD8+ T cells was substantially inhibited in the 
presence of plate-bound FasFc compared to the control groups. This inhibitory effect 
suggested that crosslinked FasL can deliver a strong negative signal to the T cells 
(Fig. 4.1.6). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.1.5. Purity of isolated T
cells. Isolated T cell sub-
populations  (A. CD4+ and B.
CD8+ T cells) were double-
stained with FITC- or PE-
conjugated antibodies to CD56
and CD3 or CD4 and CD8 right
after the purification (left panel)
or to CD3 and CD4 or CD8
after 4 days of culture (right
panel). 
4.1.6. FasL signaling inhibits
TCR/CD3 driven proliferation of
freshly isolated T cells. Cells
were stimulated for 3 days in 96F
TC plates coated with anti-CD3
mAb OKT3 (1 µg/ml) or OKT3+α-
CD28 (5 µg/ml). FasFc (25 µg/ml)
or the same amount of Fc control
protein was coated together with
the stimuli where indicated. Cells
were cultured in PRMI medium
with 10% (v/v) AB serum.
Proliferation was determined by
3H-thymidine incorporation. Data
represent mean values and
standard deviations from triplicate
wells. 
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We also observed differences in morphology of the T cells stimulated under different 
conditions. As expected, during the 4 days of culture, the cells kept in medium 
remained small and round while the stimulation led to enlargement and formation of 
proliferation clusters. Clearly, most of the cells treated with FasFc also remained small 
and round. Importantly, we did not detect an increase in the number of dead cells in 
the presence of FasFc. The differences were most obvious on day two. While the cells 
in absence of FasFc started to proliferate, the FasFc treated cells remained "silenced". 
Only on day three, some FasFc-treated cells started to proliferate but to a much lesser 
degree compared to the other groups. The flow cytometric analyses confirmed our 
observation (Fig. 4.1.7). It should be stressed that the inhibitory effect of FasL 
engagement on proliferation was observed in both CD4+ and CD8+ subpopulations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.1.7. FasL-engagement inhibits TCR/CD3-induced T cell activation. CD4+ (A)  or CD8+ (B)
T cell population were enriched as described. Cells were stimulated for 4 days in 24 well TC plates
coated with anti-CD3 mAb OKT3 (1 µg/ml) or OKT3+α-CD28 (5 µg/ml) in the presence or absence of
FasFc (25 µg/ml) or the same amount of IgGFc control protein. Cells were cultured in PRMI medium with
10% (v/v) AB serum. Activation was monitored on the basis of cell size (forward scatter) and granularity
(side scatter) determined by FACS analysis. Cells were analyzed on day 0 (left panel) and after 4 days
(right panel) of culture.  
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We also analyzed the expression of the two activation markers CD69 (known as 
activation inducer molecule, very early activation antigen, MLR-3 and Leu-23) and 
CD25 (IL-2 receptor α chain) on cells of the individual groups after 4 days of 
stimulation. As expected, both antigens were heavily induced on both CD4+ and CD8+ 
T cell subsets upon stimulation with anti-CD3 and anti-CD28 antibodies. Moreover, all 
cells cultured in the presence of plate-bound FasFc showed no or only slightly 
increased expression of both surface antigen (Fig. 4.1.8).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.1.5. FasL-engagement blocks cell-cycle progression of freshly isolated human 
peripheral T cells 
Cell-cycle analyses were also performed in parallel. The results supported the 
observations on the morphological changes of the cells. 2 days after stimulation, a 
fraction of cells started to enter into G2/S phase. On day 4, the number of cells in G2/S 
phase was further increased and only some apoptotic cells could be detected. As 
expected, co-stimulation by OKT3 and anti-CD28 lead to enhanced cell-cycle 
progression as compared to stimulation by OKT3 alone. Also activation of CD4+ T cells 
seemed to depend more on the co-stimulatory signal through CD28. Clearly, FasL-
Fig. 4.1.8. Inhibited surface expression of CD25 and CD69 of activated T cells crosslinked
with FasL. T cells (A. CD4+ or B. CD8+ T cells) were cultured in wells coated as described in Fig.
4.1.7. for 4 days. Surface expression of CD25 (upper panel) and CD69 (lower panel) was
assessed by staining with PE- conjugated α-CD25 or α-CD69 followed by FACS analysis. The
graphs show the geometric log mean fluorescence intensity.  
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engagement kept the cells resting at G0/G1 and inhibited G2/S entry. Importantly, we 
did not observe a significant increase in apoptotic cells during the 4 days culture. 
Thus, FasL-engagement resulted in growth arrest but not apoptosis of freshly isolated 
T cells. (Fig. 4.1.9).  
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Fig. 4.1.9. FasL-engagement results in cell-cycle arrest. Cell-cycle progression of T cell
subpopulations was analyzed upon isolation (A) and after 2 days (B) or 4 days (C) in culture. The cells
were then collected from individual wells, fixed and permeabilized and stained with 50 µg/ml propidium
iodide for DNA content analysis by flow cytometry. The percentages of apoptotic (apo, <2n DNA),
G0/G1 (G1, 2n DNA), and S, G2/M (>2n DNA) cells are indicated. 
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4.1.6. Exogenous IL-2 does not counteract FasL-induced inhibition of T cells 
As described before in Fig. 4.1.8, the stimulated cells treated with plate-bound FasFc 
showed no or slightly increased expression of CD25 after 4 days stimulation. To check 
whether the inhibition through FasL signal might be due to a reduced production of   
IL-2, we added additional exogenous rIL-2 into culture medium. Clearly, the 
exogenous IL-2 was not able to restore the proliferation ability of freshly isolated T 
cells (Fig. 4.1.10). When compared to effect of FasL-ligation in the absence of rIL-2 
(shown in Fig. 4.1.6), we did not observe a major effect of the growth factor.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.1.10. IL-2 does not counteract FasL effects in T cells. T cells (A. CD8+, B. CD4+ or C. E+ T
cells) were stimulated as described in Fig. 4.1.6. for 3 days in 96F TC plates. Cells were cultured in
PRMI and 10% (v/v) AB serum with exogenous added 10 U/ml rIL-2. Proliferation was determined by
3H-thymidine incorporation. Data represent mean values and standard deviations from triplicate wells.
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4.1.7. Enhanced proliferation upon FasL-engagement in T cell clones 
Then we analyzed the effects of FasL engagement on established T cell clones and 
lines. In contrast to freshly isolated T cells, engagement of FasL by plate-bound FasFc 
in T cell clones resulted in an increased thymidine uptake in response to TCR/CD3 
stimulation (either OKT3 or OKT3 and anti-CD28). Notably, cells maintained in the 
medium also showed a higher degree of 3H TdR uptake than stimulated cells. When 
comparing cells that had been restimulated for 7 or 28 days prior to the assay. The 
former one (7 days) showed a stronger inhibition of proliferation (Fig. 4.1.11). Note that 
the cells were kept in IL-2 containing medium, therefore the medium control showed a 
high degree of 3H TdR uptake. Upon restimulation, the reduction of proliferation was 
probably due to the induction of AICD, which then might be blocked by FasL-
engagement. 
 
 
 
 
 
 
 
 
 
 
 
 
4.1.8. FasL-engagement blocks cell-cycle progression of T cell clones 
Cell-cycle analyses were performed before and after 4 days of stimulation of clone 
cells which had been last restimulated 25 days before. As shown in Fig. 4.1.12, cells 
cultured in medium without exogenous added IL-2 showed a high rate of apoptotic 
DNA. The stimulation with OKT3 or OKT3 and anti-CD28 resulted in enhanced S/G2M 
progression accompanied by increased apoptosis. There was no difference where the 
cells were co-stimulated with OKT3 and anti-CD28 or only with OKT3. FasL-
engagement did not lead to enhanced proliferation or accumulated apoptosis 
compared to the stimulated cells or the un-stimulated cells. Most of the cells were kept 
Fig. 4.1.11. FasL signaling enhances TCR/CD3 driven proliferation of T cell clones. Clone cells
that had been restimulated 7days (left panel) or 28 days (right panel) were further stimulated for 3
days with the stimuli where indicated. Proliferation was determined by 3H-thymidine incorporation
with the data presents as mean values and standard deviations of triplicate culture after 3 days. 
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at the G0/G1 phase and obviously inhibited from S/G2M entry. Thus, FasL-engagement 
resulted in growth arrest but not apoptosis in T cell clones. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.1.9. Inhibition of TCR/CD3-induced tyrosine phosphorylation by FasL-
engagement 
Having demonstrated that FasL-engagement alters TCR/CD3-mediated activation, we 
tried to find whether this was also reflected in biochemical alterations of signaling 
events due to FasL ligation. Tyrosine phosphorylation mediated by non-receptor PTKs 
is required to initiate TCR/CD3-dependent activation. We therefore performed 
phosphotyrosine western blots using T cell blasts or T cell clones. We extensively 
crosslinked the FasFc with anti-human IgG (Fc-specific) mAb and anti-FasL mAb 
5G51 with rabbit anti-mouse antibody for 30 min to 1 hour prior to stimulating the cells 
with OKT3 for the indicated 2 or 5 minutes. We consistently observed a mild reduction 
of overall tyrosine phosphorylation in all the tested cells. The most obvious blockage 
Fig. 4.1.12. FasL-engagement results in cell-cycle arrest of cultured T cell clones. Clone cells
were stimulated as described in Fig. 4.1.7. Cell-cycle progression was analyzed before (A) and after
4 days (B) culture by staining the fixed cells with 50 µg/ml propidium iodide and analyzing the DNA
content by flow cytometry. The percentages of apoptotic (apo, <2n DNA), G0/G1 (G1, 2n DNA), and
S, G2/M (>2n DNA) cells are indicated. 
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Fig. 4.1.13. FasL crosslinking inhibits TCR-induced tyrosine phosphorylation. T cell blasts
(A) and CD4+ Clone cells (B) were incubated for 1 hour in the absence or presence of 50 µg/ml
FasFc crosslinked with 10 µg/ml anti-human IgG (Fc-specific), or 20 µg/ml anti-FasL mAb 5G51
crosslinked with 5 µg/ml rabbit anti-mouse IgG. Aliquots of 1.5-2х106 cells were then exposed to
10 µg/ml OKT3 mAb for the indicated time periods and lysed in 1% NP40 lysis buffer. Proteins
were separated by SDS-PAGE and blotted to nitrocellulose. Blots were immunoprobed with the
anti-pTyr mAb 4G10. (-) indicates unstimulated control and (C) indicates rabbit anti-mouse
antibody control. 
was observed in PHA blasts as shown in Fig. 4.1.13A. The protein loading was 
checked by Ponceau S staining of the blots. According to the standard molecular 
weight, we estimated that proteins at 60, 70-76, 95-100, 120-130 and 145 kDa showed 
altered tyrosine phosphorylation (Fig. 4.1.13). Regardless of the identity of the 
individual proteins, the data presented so far indicated the physical and biochemical 
crosstalk between FasL and the TCR/CD3 complex.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.1.10. In vitro phosphorylation of a casein kinase 1 motif present in the FasL 
cytoplasmic tail  
As one of the structural characteristics, the cytoplasmic tail of FasL contains a  
putative casein kinase 1 (CK1) motif (SSASS). It has been show that recombinant CK1 
is able to phosphorylate transmembrane tumor necrosis factor-α (mTNFα) in murine 
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Fig. 4.1.14. Recombinant casein kinase 1 specifically phosphorylates CK1 motif of FasL
In vitro. A. Three different GST-FasLcyto fusion protein constructs were used in our
experiments: FasLcyto contains the complete cytoplasmic tail of FasL, consisting of 80 aa (36.5
kDa); FasLcyto1 contains the N-terminal region of 29 aa (33.5 kDa) and FasLcyto2 contains the
membrane proximal proline-rich stretch with 53 aa (31 kDa). Importantly, FasLcyto and
FasLcyto1 contain the putative CK1 motif SSASS. B. The in vitro kinase assay was performed
by adding exogenous CK1 to the indicated GST fusion proteins on beads. Coomassie staining
of the loaded proteins is shown in the lower panel, the autoradiograph of incorporated
radiolabelled ATP in the upper panel. 
macrophages108. Since casein kinase motifs are present in at least the six TNF family 
members associated with retrograde signaling, the authors predicted that CK1-
dependent mechanism might explain the reverse signaling capacity of those TNF 
family members. To analyze whether CK1 may also be involved in the reverse 
signaling of FasL, we performed an in vitro kinase assay in which we added 
exogenous CK1 to GST fusion proteins that contain different parts of the cytoplasmic 
tail of FasL (Fig. 4.1.14A). In fact, we observed that the fragments containing the 
putative CK1 substrate motif (FasLcyto1 and FasLcyto) were more heavily 
phosphorylated than the GST control and the FasLcyto2 (Fig. 4.1.14B). The finding 
that CK1 can phosporylate the cytoplasmic tail of FasL might help to get further 
insights into the potential signaling capacity of this motif in the future.  
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4.2. Defining FasL interacting proteins  
Hematopoietic and non-hematopoietic cells differ in the composition of the lysosomal 
compartment. Only in specialized hematopoietic cells (e.g. T cells, NK cells, mast cells 
and macrophages), so-called secretory lysosomes are found21. It was suggested that 
FasL is located into these secretory lysosomes by virtue of protein-protein interaction 
mediated via its proline-rich cytoplasmic 
region17,86. Thus, in our studies we 
aimed at identifying molecules that 
regulate FasL localization to the 
secretory lysosomes. We initially 
started to search for suitable cell lines 
by analyzing the FasL localization upon 
transfection. Each cell line was 
transfected with a GFP-tagged human 
FasL construct. Under these conditions, 
in non-hematopoietic cell lines (HeLa, 
HaCaT and 293T), FasL-GFP was 
mainly expressed at the plasma 
membrane. In contrast, transfection of 
hematopoietic cell lines (Jurkat, HUT78 
and RBL2H3) resulted in a distribution 
of FasL-GFP to intracellular granules as 
shown in Fig. 4.2.1. These results 
suggest that different sorting motifs or 
proteins may exist that regulates FasL 
lysosomal or surface expression. The 
proline-rich domain (PRD) in the 
intracellular tail of FasL is likely to 
contain such sorting motifs. 
Identification of FasL interacting proteins that bind to this docking site would enable us 
to investigate the molecular mechanism of differential protein trafficking in 
hematopoietic and non-hematopoietic cells. In previous work of this group, various 
parts of the intracellular region of FasL expressed as GST fusion proteins (see Fig. 
3.2.1) were used to precipitate FasL binding proteins from T cell lysate113. The 
Fig. 4.2.1. Expression of FasL in different cells.
FasL-GFP was transiently expressed in the non-
hematopoietic cell lines A. Hela, B. HaCaT and C.
293T or hematopoietic cells D. Jurkat, E HUT78
and F RBL. 24 hours after transfection, cells were
fixed and analysed by confocal microscopy. 
B. HaCaT E. HUT78
F. RBL
D. JurkatA. HeLa
C. 293T    
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precipitates were separated by two-dimensional gel electrophoresis and sequence 
information was obtained by MALDI-TOF-based peptide finger-print analyses. With 
PACSIN2 (= protein kinase C and casein kinase substrate in neurons 2) and FBP17 (= 
formin binding protein 17), two structurally related proteins were identified that are 
likely to be involved in protein trafficking and cytoskeletal organization113. These two 
proteins belong to a larger family of structurally related polypeptides characterized by 
a similar modular composition of so-called FCH (Fes/CIP4 homology) and SH3 
domains. We named it “FCH/SH3 protein family”. Besides PACSIN2 and FBP17, the 
PACSIN isoforms PACSIN1 and PACSIN3, CD2BP1/PEST PIP (= CD2 cytoplasmic 
tail-binding protein1 or proline-serine-threonine phosphatase interacting protein), CIP4 
(= cdc42 interacting protein 4), the RhoGAP C1 (= Rho-GTPase-Activation 
hematopoietic protein C1), the hypothetical protein KIAA0456 (which has a 
comparable domain structure with Rho GAP C1) and the hypothetical FLJ00007 
protein (which contains two SH3 domains) belong to this family (Fig. 4.2.2). Since all 
known proteins of this family are involved in cytoskeletal reorganization and lysosomal 
transport in different cellular systems, we wondered whether they could bind to FasL 
and whether the association and co-expression together with FasL would alter the 
subcellular localization of FasL. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.2.2. The modular composition of “FCH/SH3-family”. FBP17 and PACSIN2 belong to a
family of structurally related proteins which share an overall composition with an N-terminal FCH
(Fes/CIP4 homology) domain, a central coiled-coil region and a C-terminal SH3 domain (except
FLJ00007 which contains two SH3 domains). 
FBP17 
PACSIN2
PACSIN1
PACSIN3
CIP4
FLJ00007
KIAA0456 
CD2BP1/PEST PIP
Rho GAP C1
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4.2.1. The interaction of FasL with FCH/SH3 proteins is mediated by SH3 
domains 
As reported earlier, we could clearly demonstrate the interaction of FasL with SH3 
domains of PACSIN2 and FBP17113. This was verified when we used fusion proteins 
containing full length PACSIN2 wild-type (wt) or mutants (P478L). As shown in Fig. 
4.2.3, a single point mutation (P478L) within the PACSIN2 SH3 domain completely 
abrogated FasL binding. 
 
 
 
 
 
 
 
 
 
 
 
 
In fact, as shown in Fig. 4.2.4, isolated SH3 domains of most if not all FCH/SH3 family 
member precipitated FasL from stable transfectants (KFL-9 or JFL-39). In this 
particular exploit, we demonstrated the binding of SH3 domains of eight different 
members of the FCH/SH3 family to FasL. With the exception of CIP4, all proteins 
expressed in vitro bind with a similar affinity. Note that from KFL cells, SH3 domains 
consistently precipitated FasL as a double band and from JFL as a signal band.  
 
 
 
 
 
 
 
 
 
 
Fig. 4.2.4. FasL interacts with
the SH3 domain of FCH/SH3
proteins. 25 µg of indicated
GST-SH3 domain fusion proteins
on glutathione beads were
incubated with lysates prepared
from 20x106 KFL-9 or JFL-39
cells. Coomassie staining (lowest
panel) and anti-FasL
immunoblotting (upper and
middle panel). Precipitates with
anti-FasL mAb NOK1 and GST
served as positive and negative
controls. 
Fig. 4.2.3. FasL interacts with PACSIN2 via
SH3 domain. GST fusion proteins containing
full length PACSIN2 wt or P478L were used to
precipitate FasL from lysates of human T cell
PHA blasts stimulated with TPA and ionomycin
for five hours. For each precipitation, 90x106 T
cell blasts were used in 1 ml lysate buffer.
Ponceau S staining (left panel) and anti-FasL
immunoblotting (right panel). Precipitates with
anti-FasL mAb NOK1 of the same lysate
served as a positive, GST as a negative
control.
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4.2.2. FasL coprecipitates with FCH/SH3 proteins 
Having shown that the SH3 domains of FCH/SH3 proteins interact with FasL in in vitro 
“pull down” assays, we tried to get in vivo evidence for the interaction. To this end, 
vectors encoding myc-tagged full length FCH/SH3 proteins (including FBP17, 
PACSINs, CD2BP1 and CIP4∆CC that lacks part of coiled-coil region) were 
transfected individually or together with a FasL expression vector (pl217s or 
FasLpEFBOS) into 293T cells. We also expressed FBP17 lacking the SH3 domain 
(FBP17-SH3) and PACSIN2 with a point-mutation in the SH3 domain 
(PACSIN2P478L) to assess the role of SH3 domains in the interaction with FasL. It 
should be mentioned that all the constructs used in the experiments are of human 
origin except the PACSIN2 and PACSIN2P478L proteins which were of murine origin. 
Sequence analysis reveals that murine PACSIN2 shares 87% homology with the 
human protein and that the SH3 domain (amino acid 535-485) is in fact identical (Fig. 
4.2.5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cell lysates were used 24 hours post transfection for co-immunoprecipitation analyses. 
The interactions of FasL with myc-tagged FCH/SH3 proteins were detected in two 
ways: either anti-FasL mAb was used for precipitation to detect the co-associated 
proteins with anti-myc immunoblotting or anti-myc mAb was used for IP followed by 
Fig. 4.2.5. Sequence alignment for murine and human PACSIN2. Data were batched from
GeneBank database and analyzed with “BLAST” software from NCBI. Asterisks indicate
identical amino acids in the FCH and SH3 domains. 
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anti-FasL western blot. Protein expression was analyzed by stripping the blots and re-
probing them with the same antibodies used for precipitation, or alternatively by 
probing the cell lysates with anti-FasL and anti-myc antibodies. As shown in Fig. 4.2.6, 
anti-myc immunoprecipitation followed by FasL staining of the western blot revealed 
the interaction of FasL with all the full length proteins tested. Importantly, FasL was 
only co-precipitated in the presence of intact SH3 domains. On the other hand, when 
FasL was precipitated from double transfectants, only PACSIN2 was detected as co-
precipitated myc-tagged material. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.2.6. FasL co-precipitates with
FCH/SH3 proteins. Wild-type or mutated
FCH/SH3 proteins were transiently transfected
into 293T cells as myc-tagged fusion proteins
alone or co-transfected with FasL by the
calcium phosphate method. NP40 lysates were
made 24 hours after transfection. The lysates
were split into two aliquots for parallel
immunoprecipitation (IP) with anti-CD95L or
anti-myc mAb as indicated. Proteins were
transferred to nitrocellulose and analyzed with
anti-CD95L and anti-myc antibodies (A, B
obtained from two different experiments). 
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4.2.3. FasL co-localizes with FCH/SH3 proteins 
Next, we analyzed the intracellular distribution of FCH/SH3 proteins in 293T 
transfectants and their interactions with FasL. As shown in Fig. 4.2.7, When FCH/SH3 
proteins were expressed in 293T cells, the PACSINs appeared mostly cytosolic. 
FBP17 seemed to be expressed in the cytosol as well in compartment underneath the 
cell membrane. CD2BP1 and CIP4∆CC 
were also localized in different 
distribution in the cytosolic to intracellular 
structures. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As shown in Fig. 4.2.8, when co-expressed, FasL co-localizes with the respective 
FCH/SH3 protein. Importantly, we did not detect co-localization of FasL with mutated 
PACSIN2, indicating once again that the interaction was mediated by the SH3 domain. 
As shown before in Fig. 4.2.1, FasL was mainly expressed at the cell membrane in 
293T transfectants. In contrast, we noticed that the presence of FCH/SH3 proteins 
seemed to influence the subcellular localization of FasL from the membrane into 
intracellular vesicles, possibly lysosomes. Therefore, FCH/SH3 proteins might regulate 
FasL lysosomal targeting and surface expression.  
Fig. 4.2.7. Intracellular distribution of
FCH/SH3 proteins Individual myc-tagged
FCH/SH3 proteins were expressed in 293T
cells. 24 hours after transfection, cells were
fixed, permeabilized and stained with anti-
myc mAb and Alexa Fluor 546 conjugated
goat anti-mouse secondary antibody
(gam/Alexa Fluor 546). The images were
analyzed with a Zeiss laser scanning
microscope (Zeiss LSM 510). 
FBP17 PACSIN2
CIP4∆CCCD2BP1
PACSIN3PACSIN1
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4.2.4. FCH/SH3 proteins co-localize with FasL in the lysosomal compartment 
So far, we identified the SH3 domain-mediated interaction of FCH/SH3 protein with 
FasL. Intracellular staining also indicated that members of this protein family might be 
involved in regulating FasL intracellular trafficking and lysosomal targeting. To confirm 
this assumption, besides 293T cells, we assessed the effect of some FCH/SH3 
proteins on the distribution of FasL in either the non-hematopoietic cell line HeLa or 
the hematopoietic cell line RBL2H3. Myc-tagged FCH/SH3 proteins and FasL-GFP 
were expressed and their subcellular distribution in relation to lysosomes was 
examined by laser scanning microscopy.  
 
Fig. 4.2.9 demonstrates that in HeLa cells, the presence of FBP17 (A), PACSIN2 (B, 
left panel), CIP4∆CC (C), CD2BP1 (D) directed the surface expression of FasL to 
intracellular compartments. A large amount of the protein was co-localized with the 
lysosomal and late endosomal marker Cathepsin D (CTSD) or another lysosomal 
marker lamp1 (lysosome associated membrane protein 1). As expected, 
PACSIN2P478L did not co-localize with FasL or CTSD (B, right panel).  
Fig. 4.2.8. The interaction of FCH/SH3 proteins with FasL. FasL-GFP was transiently
expressed together with the individual FCH/SH3 proteins in 293T cells. 24 hours after transfection,
cells were fixed, permeabilized and stained with α-myc mAb and gam/Alexa Fluor 546. The
individual images were analyzed by Zeiss LSM 510 and merged to demonstrate the co-localization
of FasL and the indicated proteins. 
FasL PACSIN1 mergeFasL FBP17 merge
FasL PACSIN2 merge FasL PACSIN2P478L merge
FasL CIP4 ∆CC merge FasL CD2BP1 merge
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Fig. 4.2.9. FCH/SH3 proteins co-localize with FasL in the lysosomal compartment in HeLa
cells.  
Myc-tagged FCH/SH3 proteins and FasL-GFP were co-expressed in HeLa cells by
electroporation. 24 hours after transfection, cells were fixed by 3% PFA and stained with
indicated antibodies to visualize the myc-tagged proteins and the lysosomal compartment. All
samples were stained with secondary antibodies as controls. Samples were analysed by Zeiss
LSM 510 with the laser 633, 546 and 488. The merged images show the co-localization of
indicated proteins.  
A. Co-localization of FBP17 with FasL and Cathepsin D (CTSD). Cells were transfected with
FBP17 and FasLEGFP and stained with α-myc mAb and α-Cathepsin D (CTSD) pAb followed
by CY5 conjugated donkey anti-mouse and donkey anti-rabbit rhodamine conjugated antisera.  
B. SH3 domain-mediated co-localization of PACSIN2, FasL and Cathepsin D. Wild-type
myc-tagged PACSIN2 (left panel) or PACSIN2P478L (right panel) constructs were used for
transfection with FasLEGFP and stained as described in A. 
B
Cathepsin DPACSIN2 FasL
merge merge
FasL
merge merge
PACSIN2P478L Cathepsin D
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Fig. 4.2.10. shows that in RBL2H3 cells, although FBP17 (A, left panel) and PACSIN2 
(B, left panel) co-localized with FasL, the distribution of FasL was restricted to the 
intracellular areas. Expression of FasL was detected in enlarged granules surrounding 
the lysosomal compartment stained with Cathepsin D. Again, the SH3 domain mutants 
did not show the co-localization with FasL (A, right panel for FBP17-SH3 and B. right 
panel for PACSIN2 P478L). Interestingly, as indicated in Fig. 4.2.10C, CD2BP1 co-
localized with FasL in membrane protrusions of RBL2H3 cells indicating a potential 
influence on rearrangement of the cytoskeleton. 
Fig. 4.2.9. FCH/SH3 proteins co-localize with FasL in the lysosomal compartment in HeLa
cells.  
C. Co-localization of CIP4∆CC and FasL with lamp1. CIP4∆CC and FasLEGFP were
expressed and immunostaining was carried out by using either α-myc (left panel) or α-lamp1
(right panel) mAb. Gam/Alexa Fluor 546 was used as secondary antibody in both cases. 
D. CD2BP1 co-localizes FasL with Cathepsin D and lamp1. HeLa cells co-transfected with
CD2BP1 and FasLEGFP were stained with either α-lamp1 mAb as described in C (upper
panel) or α-myc mAb together with α-Cathepsin D (CTSD) pAb as described in A (lower panel).
CIP4∆CCFasL Merge lamp1FasL merge
C
D
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Merge
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Fig. 4.2.10. FCH/SH3 proteins co-localize with FasL in the lysosomal compartment in RBL2H3
cells. Myc-tagged FCH/SH3 proteins and FasL-GFP were co-expressed in RBL2H3 cells by
electroporation. 24 hours post transfection, cells were stained and analyzed as described in Fig. 4.2.9. 
A. Cells were transfected with FBP17 (left panel) or FBP17-SH3 (right panel) and FasLEGFP and
stained with α-myc mAb followed by gam/Alexa Fluor 546.  
B. Wide type Myc-tagged PACSIN2 (left panel) or PACSIN2P478L (right panel) constructs were used
for co-transfection and stained with α-myc mAb and α-Cathepsin D (CTSD) pAb followed by CY5
conjugated donkey anti-mouse and donkey anti-rabbit rhodamine conjugated antisera. 
C. Co-transfection of CD2BP1 with FasLEGFP and staining with α-myc mAb followed by gam/Alexa
Fluor 546. 
FasLEGFP CD2BP1 merge
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Cathepsin DPACSIN2P478L FasL
merge merge
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4.3. FasL interacts with Nck1: linking FasL and the cytoskeleton to the TCR/CD3 
complex? 
Cytotoxicity exerted by T lymphocytes and NK cells is in part mediated by FasL and 
potentially other members of the TNF family. Upon receptor-induced fusion of 
intracellular secretory lysosomes with the plasma membrane, FasL reaches the cell 
surface and may trigger target cell apoptosis to help the action of perforin and 
granzymes. From earlier studies we knew that Nck1 can bind to FasL in vitro by virtue 
of two of its three SH3 domains112. Nck1 is a classical 
adaptor protein that consists of one SH2 and three SH3 
domains (Fig. 4.3.1). It is one of the molecules involved 
in cytoskeletal rearrangement and formation of the 
immunological synapse132. Therefore we asked the 
question whether Nck1 might be involved in the 
regulation of FasL transport and expression to the 
immunological synapse.  
 
4.3.1. Degranulation and surface expression of FasL in T cells 
Degranulation of FasL in T cell blasts 
We examined changes in expression of FasL in different T cell populations in the 
course of activation. T cell blasts were stimulated with TPA/ionomycin for five minutes 
up to three hours. The cells were stained with the anti-FasL antibody NOK1 and 
examined by laser scanning microscopy. As shown in Fig. 4.3.2, in un-stimulated cells 
FasL was localized in well defined intracellular granules. Under these conditions, no 
FasL appeared to be detectable on the cell surface. After 30 minutes of stimulation, 
FasL was detectable at the plasma membrane and after 105 minutes, FasL appeared 
to be almost completely transported to the surface since hardly any FasL remained 
inside the cell. 
 
 
 
 
 
 
 
0 5 min 30 min 105 min 165 min
Fig. 4.3.2 Degranulation of FasL in re-activated T cell blasts. T cell blasts were stimulated with 10 ng/ml
TPA and 500 ng/ml ionomycin for indicated time intervals and fixed at -20 °C with methanol for 5 minutes.
Cell were labelled with the anti-FasL antibody NOK1 and CY5-conjugated goat anti-mouse antisera and
examined by Zeiss LSM 510.  
Fig. 4.3.1. The modular
composition of Nck1. It
contains three N- terminal SH3
domains and one C-terminal
SH2 domain. The 2nd and 3rd
SH3 domains were shown to
bind to FasL.  
1       2          3
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Surface expression of FasL in T cell clones 
Cloned T cell populations were also tested for changes of FasL expression. To this 
end, we stimulated clone cells with TPA/ionomycin for different time intervals and 
examined the surface expression of FasL by flow cytometry. As shown in Fig. 4.3.3, in 
both CD4+ and CD8+ T cells, two peaks of FasL expression were detected during three 
hours of stimulation. The first peak developed after approximately 10 minutes. 
Following downregulation with a minimum at around 60 minutes, another increase of 
FasL expression after 2 hours was observed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.3.3. Surface expression of FasL in T cell clones. Different clone cells were stimulated with
TPA and ionomycin for indicated time intervals. Surface expression of FasL was assessed by
staining with anti-FasL mAb 5G51 and gam/PE followed by FACS analysis. PE-conjugated IgG1 was
used as isotype control. A. The histograms show the fluorescence intensity of FasL in comparison to
isotype control (filled histograms). B. The graphs indicate the mean fluorescence intensity at
different time points. 
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Lysosomal localization of FasL in T cells 
To characterize the intracellular localization of FasL in T cells, we double-stained FasL 
and Cathepsin D in Jurkat cells constitutively expressing FasL (JFL). As shown in   
Fig. 4.3.4, there was a substantial overlap between FasL and Cathepsin D. 
Interestingly, in addition to the granules containing both molecules, some vesicles 
lacking FasL were visible as well structures with FasL only. 
 
 
 
 
 
 
 
 
Trafficking of FasL in superantigen-activated T cell clones 
Besides using TPA/ionomycin to induce an intracellular Ca2+ flux and trigger T cell 
degranulation, we also stimulated superantigen-reactive T cell clones with SEA to 
analyzed the transport of FasL. In this case, cells were stimulated by coverslip-bound 
SEA for 1 hour and the expression of FasL and Cathepsin D was detected by staining 
with antibodies. As shown in Fig. 4.3.5, in stimulated clone cells, both FasL and 
Cathepsin D were moved towards a protruding cell pole (A). In some cells, FasL was 
expressed on the cell surface and separated from Cathepsin D (B). 
 
 
 
 
 
 
 
 
 
 
Fig. 4.3.4. Co-localization of FasL with the lysosomal
marker Cathepsin D in T cells. FasL stable transfectants of
Jurkat cells (JFL) were stained with anti-FasL mAb NOK1 and
anti-Cathepsin D pAb followed by Alexa fluor 488-conjugated
goat anti-mouse (gam/Alexa fluor 488) and rhodamine-linked
donkey anti-rabbit antibodies. The image was analyzed by
Zeiss LSM 510 and showed the FasL (green), Cathepsin D
(red) and the co-localization (yellow). 
Fig. 4.3.5. Transport of FasL in SEA-activated clone cells. Cells of the CD4+ clone were stimulated
on coverslips with SEA for 1 hour before fixation and staining for FasL and Cathepsin D (CTSD).The
images to the right represent overlays to indicate co-localization of the two proteins. A and B were two
typical images chosen from one experiment.  
FasL CathD merge FasL CathD merge
A B
PART 4 -78- RESULTS 
 
Trafficking of lysosomes in cytotoxic T cells stimulated by target cells 
We also investigated the trafficking of lysosomes in T cells stimulated by target cells in 
vivo. γδ T cells (clone EP3) were pre-stained with Lysotracker Red DND-99 to visualize 
lysosomes and given to melanoma-derived fibroblasts (MeWo) in the presence of 
phosphoantigen BrHPP. The cells were analyzed by laser scanning microscopy and 
sequential images were acquired. According to the images shown in Fig. 4.3.6, EP3 
cells were "attracted" by the MeWo cells within 10 minutes. Upon contact, the 
lysosomes of EP3 cells were targeted towards the contact area and released. This 
caused the MeWo cells to become round and detach from the coverslip. The MeWo 
cells died after approximately 80 minutes.  
 
 
 
 
 
 
 
 
 
 
 
4.3.2. Interaction of FasL with Nck1 
Clearly, lysosomes containing cytotoxic material were moved to the contact area of T 
cells and target cells. The next question to address was which molecules might be 
directing FasL and the lysosomes to the forming cytotoxic synapse. Looking back to 
the interactions that had been identified earlier112, one candidate was Nck1. In the 
meantime Nck1 had been described as an adaptor that links the TCR and the 
cytoskeleton to move molecules to the immunological synapse132. Therefore, the idea 
was that Nck1 might also be involved in the movement of secretory lysosomes to the 
cytotoxic synapse. 
 
To characterize the interaction of FasL and Nck1, we used the same strategies 
described for the interaction of FasL and FCH/SH3 family proteins: "pull down", co-
0 min 10 min 60 min 80 min30 min
Fig. 4.3.6. Release of lysosomal content during targeting of tumor cells by γδ T effectors.
MeWo cells were grown on Lab-TekII chambered coverslips for 24 hours. 1x106 EP3 cells pre-
stained with 50 nM Lysotracker Red DND-99 were loaded in the presence of 20 nM BrHPP. Cells
were examined by confocal microscopy and sequential images were acquired every minute up to
2 hours. Laser 546 was used to monitor the lysosomal compartment stained with Lysotracker Red
and a light transmission was used to show the cell morphology changes.  
PART 4 -79- RESULTS 
 
precipitation and co-localization assays. According to the structure of Nck1 (Fig. 4.3.1), 
a series of GST-, Myc- or GFP- tagged constructs encoding different domains of Nck1, 
either wild-type or point mutated, were used in the experiments.  
 
"Pull down" 
Earlier results from this group indicated that the 2nd and 3rd SH3 domain of Nck1 might 
interact with FasL112. In this experiment, besides the separated SH3 or SH2 domains, 
we also used fusion proteins containing the combination of the three SH3 domains or 
full length protein. In case of "mutants", either one of the separated domain or all the 
three SH3 domains were mutated. Both KFL-9 or JFL cell lysates were used for “pull 
down” assays. As shown in Fig. 4.3.7, besides the 2nd and 3rd SH3 domain of Nck, the 
combined three SH3 domains and the complete protein also interact with FasL. A 
single SH3 mutation resulted in milder interaction. Only when all three SH3 domains 
were mutated, the binding was abolished. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.3.7. FasL interacts with two out of three SH3 domains of Nck1. 40 µg of indicated GST-
SH3 domain fusion proteins on glutathione sepharose beads were incubated with lysates
prepared from 20x106 KFL-9 or JFL cells. The proteins were separated by SDS-PAGE followed by
anti-FasL western blotting. Precipitates with anti-FasL mAb NOK1 of the same lysate served as a
positive control. Ponceau S staining (lowest panel) and anti-CD95L immunoblotting (upper and
middle panels). 
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Co-precipitation 
Vectors encoding wild-type, SH2 mutated and all the SH3s mutated myc-tagged Nck1 
were transfected together with a FasL expression vector into 293T cells. Cell lysates 
(24 hours post transfection) were subjected to anti-FasL or anti-myc immuno-
precipitation. As shown in Fig. 4.3.8, Anti-myc immunoprecipitation followed by FasL 
staining revealed co-precipitated FasL in the presence of wild-type and SH2 mutants 
of Nck1 but not when the SH3s were mutated. The use of anti-FasL mAb for 
precipitation revealed similar results: only the wild-type and SH2 mutated but not the 
SH3s mutated myc-tagged Nck1 was detected as co-precipitated protein. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Co-localization 
Wild-type or mutated GFP-tagged Nck1 were co-expressed with FasL in either 293T or 
RBL2H3 cells. 24 hours after transfection, the cells were fixed and the co-localization 
was analyzed by staining with anti-FasL antibody NOK1. As shown in Fig. 4.3.9A, 
FasL colocalizes with wild-type or SH2 point mutated (R308K) Nck1 but not with the 
mutants carrying a point mutation in any of the three SH3 domains (W38K, W143K or 
W229K). Like shown for FCH/SH3 proteins, we also noticed that the presence of Nck1 
changed the intracellular distribution of FasL from the membrane into intracellular, 
Fig. 4.3.8. FasL co-precipitates with
Nck1. Myc-tagged proteins were
transiently co-expressed with FasL in
293T cells. Cell lysates prepared 24
hours after transfection were split into
two aliquots for parallel immuno-
precipitation (IP) with α-FasL mAb
NOK1 or α-myc mAb 9C11. Proteins
were transferred to nitrocellulose
followed by western blotting (WB).
α-myc IP followed by α-FasL WB
revealed co-precipitated FasL and α-
FasL IP followed by α-myc staining
revealed co-precipitated myc-tagged
proteins. To monitor protein
expression, the blots were stripped and
stained with α-myc (for α-myc IP) and
α-FasL (for α-FasL IP).  
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lysosome-like vesicles. Notably, in RBL2H3 cells, Nck1 co-localized with FasL but the 
interaction did not alter the intracellular localization of FasL. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.3.3. Co-localization of FasL with Nck1 in activated cytotoxic T cells 
Having shown that Nck1 co-localizes with FasL when overexpressed, we tried to 
detect the interaction of the two proteins in mature human T cells. Firstly, we checked 
the subcellular distribution of Nck1 by staining with anti-Nck1 antibody. As shown in 
Fig. 4.3.10A, Nck1 is expressed as a cytosolic protein and does not localize in 
FasLNck1 WT Merge
FasLNck1 W38K Merge
FasL Nck1 W143K Merge
FasLNck1 W229K Merge
FasLNck1 R308K Merge
A
Nck1 WT Nck1 FasL merge
B
Fig. 4.3.9. Intracellular distribution of FCH/SH3 proteins and the interaction with FasL. A.
Wild-type (WT) or mutated Nck1 were co-expressed with FasL in 293T cells. 24 hours after
transfection, cells were fixed, permeabilized and stained with α-FasL mAb NOK1 and gam/Alexa
fluor 546. The samples were analyzed confocal microscopy. B. Co-localization of Nck1 with FasL
in RBL2H3 transfectants.  
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intracellular vesicles in T cells. Upon activation with superantigen sensitive CD8+ T cell 
clones; both Nck1 and FasL co-localized with Cathepsin D in pseudopodia-like 
protrusions. (Fig. 4.3.10B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.3.4. Co-localization of Nck-1, FasL and Cathepsin D in the contact region 
between cytotoxic CD8+ T and target cells 
As mentioned, TCR-triggered recruitment of Nck1 to CD3ε is essential for T cell 
receptor signaling and synapse formation132. From our results, the capacity of Nck1 
binding to FasL in activated T cells raises the hypothesis that Nck1 couples the actin 
cytoskeleton to FasL within the T cell/target cell contact region during T cell activation. 
To address this, we next generated cytotoxic CD8+ T cell lines (cytotoxicity were 
confirmed by chromium release assay as shown in Fig. 4.3.11A) and used these cells 
for T cell/target B cell conjugate assay. The induction of synapse formation was 
examined by evaluation of the actin distribution by phalloidin staining. As shown in Fig. 
4.3.11B, actin accumulation could be observed at the T cell/target B cell contact site. 
Pretreatment of T cells with latrunculin A or cytochalasin D (Fig. 4.3.12A) to block actin 
Fig. 4.3.10. Intracellular distribution of Nck1 and the interaction with FasL. A. Intracellular
distribution of Nck1 was analyzed by immunostaining with anti-Nck1 mAb and gam/Alex fluor 488
in indicated T cells. B. SEA superantigen sensitive CD8+ T cell clones were stimulated on
coverslips with 0.5 ng/ml SEA for 1 hour before they were fixed and stained for FasL and
Cathepsin D (left panel) or stained for Nck1 and Cathepsin D (right panel). The images were
merged to show the co-localization and normal transmission light was used to show the
protrusion forming in activated cells.  
T cell clone T cell blasts JFL14
A
FasL Cathepsin D merge Nck Cathepsin D merge
B
SEA-activated CD8 T cells
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polymerization resulted in abrogated synapse formation (Fig. 4.3.12B). Importantly, as 
shown in Fig. 4.3.13, both Nck1 and FasL were located at the T cell/target B cell 
contact site.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.3.11. Cytotoxicity of CD8+ T cell lines and the synapse formation in T cell/target B
cell interface. A. CD8+ lines (CD8-O and CD8-M) were used as effector cells against EBV
transformed B cells (EBV-O, EBV-M) in a chromium-51 (51Cr) release assay. Data present the
percentage of specific lysis at different effector/target cell ratios (E/T ratio). B. T cells were either
unstimulated (left panel) or incubated with target B cells (right panel), fixed, permeabilized, and
stained for actin by using rhodamine conjugated phalloidin. Normal transmission light was used to
show cell shapes. 
CD8
Cytochalasin D
Latrunculin A
Medium
CD8/EBV-B
BA
Fig. 4.3.12. Actin cytoskeleton-dependent synapse formation in T cell/target B cell
interface. A. Actin polymerization can be blocked either by latrunculin A, which sequesters
monomeric G-actin in a 1:1 molar ratio and prevents its addition to growing filaments, or by
cytochalasin D, which caps the barbed end of filaments, thereby precluding addition of new G-
actin monomers. B. CD8+ T cells were preincubated with 5 nM latrunculin A or 10 µM
cytochalasin D for 30 minutes before the conjugation assays was carried out. Rhodamine-
phalloidin was used to stain the actin filaments as described in Fig. 4.3.11B. 
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4.4. Other FasL interacting proteins and the potential role in the regulation of 
FasL expression  
In 1996, Hachiya and coworkers deposited several protein fragments in the NCBI 
database that were found to interact with FasL in a yeast two-hybrid screen. Although 
these "Fas-ligand associated factors" (FLAF1-3 - AAB93495, AAB93496, AAB93497) 
contained either a WW domain (FLAF1) or one or more SH3 domains (FLAF2,3) no 
further results were published except a note that FLAFs might regulate FasL stability. 
Sequence comparison with novel entries in the databases reveals that FLAF-1 forms 
part of the formin binding protein 11 (FBP11, also called the huntingtin-interacting 
protein HYPA), FLAF2 is part of the c-Cbl-associated protein SH3P12 = "sorbin and 
SH3 domain containing 1", and FLAF3 represents a portion of the BAI1-associated 
protein 2 (BAP2)-beta (Fig. 4.4.1). We therefore studied the interaction between 
FLAFs and FasL. First of all, we used GST-fusion proteins containing WW domain of 
FLAF1, 1st or 3rd SH3 domain of FLAF2 and SH3 domain of FLAF3 for in vitro "pull 
down" assays. As expected, all proteins could precipitate FasL from KFL-9 cell lysates 
(Fig. 4.4.2A). We also constructed myc-tagged expression vectors encoding full length 
SH3P12/FLAF2 and BAP2β/FLAF3 and transfected them together with FasL into 293T 
cells. Co-immunoprecipitation (Fig. 4.4.2B) or intracellular staining (Fig. 4.4.2C) 
confirmed the protein-protein interaction. Interestingly, the interaction of FLAF2 and 
FLAF3 with FasL did not result in translocation of FasL into intracellular vesicles but 
rather enhances the surface expression of FasL. 
Fig. 4.3.13. Co-localization of Nck1 and FasL in the contact zone of T cells and target B cells.
T cells and B cells were mixed at the ratio of 2:1 and co-cultured for 20 minutes. After conjugation,
cells were fixed, permeabilized and stained for Nck1, FasL and Cathepsin D by biotinylated anti-FasL
mAb NOK1 with streptavidin-FITC, anti-Nck1 mAb with CY5-goat anti-mouse and anti-Cathepsin D
with rhodamine-donkey anti-rabbit antibodies. Samples were examined by Zeiss LSM 510. The
“merged” image shows the overlay of three proteins and the normal transmission light was used to
show T cell: target B cell interface. 
FasL Cath DNck1 merge Light
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Fig. 4.4.2. Protein-protein interaction
of FasL with FLAFs. A. GST-fusion
proteins were used for in vitro "pull down"
assays and the precipitated FasL was
detected by immunoblotting with anti-
FasL mAb G247-4. B. Myc-tagged
proteins were co-expressed with FasL in
293T cells followed by co-precipitation
assays. C. Intracellular distribution of
SH3P12/FLAF2 and BAP2β/FLAF3 and
the co-localization with FasL in 293T
transfectants. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.4.1. Fas ligand associated factors (FLAFs). The modular composition of FLAFs were
indicated in frames. Sequence comparison with novel entries in the databases reveals that FLAF1
forms part of the formin binding protein 11 (FBP11, also called the huntingtin-interacting protein
HYPA) which contains 3 WW domain, FLAF2 is part of the c-Cbl-associated protein SH3P12 =
"sorbin and SH3 domain containing 1" which contains three SH3 domains, and FLAF3 represents
a portion of the BAI1-associated protein 2 (BAP2)-β and contains one SH3 domain. 
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5. Discussion 
5.1. Reverse signal transduction of FasL in T cells 
As stated in the introduction, FasL reverse signaling so far has been exclusively 
demonstrated in the context of murine T cell populations. Thus, Suzuki, Fink and 
colleagues reported that expression of functional FasL and its engagement is required 
to induce maximal proliferation and cytotoxic effector function of CD8+ T cells68,69,71. In 
contrast, for CD4+ cells, cell-cycle arrest followed by elevated levels of apoptosis was 
observed when cells were activated by TCR- and FasL-stimulation70. Thus, it seemed 
that FasL-engagement would exert positive and negative signals depending on the T 
cell subpopulation under investigation. In our experiments, we mostly observed a 
negative regulation of TCR or TCR/CD28-induced T cell activation in response to 
FasL-ligation. Thus, in unseparated (E+) as well as in purified CD4+ and CD8+ T cells, 
FasL-engagement resulted in a marked decrease of proliferation associated with a 
reduced expression of activation markers and an arrest in cell-cycle progression. 
However, we also observed a "stimulatory" effect of FasFc fusion protein or anti-FasL 
antibody crosslinking on the proliferation of pre-activated T cell populations. Under 
these conditions, we suggest that FasL ligation might have resulted in decreased 
sensitivity towards activation-induced cell death associated with increased survival and 
thymidine incorporation in the presence of IL-2 as a growth factor. We assume that the 
reported differences or "dual function" of FasL in different T cell populations are rather 
due to the state of activation than to the phenotype of the given T cell population. 
 
Interestingly, for more than 15 donors tested, we observed a major reduction of 
proliferation of freshly isolated PBMC or T cells in the presence of FasFc. Clearly, 
FasL crosslinking was absolutely required to exert this inhibitory effect. This result is 
compatible with the reported observations for murine CD4+ T cells70. However, 
whereas Desbarats and colleagues could overcome the inhibitory effect of FasL by 
adding recombinant IL-2, we (and Suzuki et al.69) did not see a major difference in the 
presence or absence of IL-2 on primary cells. Only in T cell blasts, we observed a 
restoration of proliferative capacity in the presence of exogenously added growth 
factor. We did not see any major effect of IL-2 on unseparated (E+) T cells, nor on 
purified CD4+ or CD8+ T cells. Further, in this context it did not matter whether the cells 
were stimulated with anti-CD3 alone or in combination with anti-CD28. In all cases, 
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proliferation was significantly reduced by FasL-crosslinking with FasFc or anti-Fas 
mAb. 
 
As further parameters for the analysis of FasL-effects, we determined changes in cell 
morphology, expression of classical activation markers (CD25 and CD69), and cell-
cycle progression. Once again, we compared purified CD4+ or CD8+ T cells in order to 
consider the suggested dual function of FasL on different T cell subsets. As for the 
proliferation, for all other tested parameters, we detected almost the same outcome of 
FasL-ligation on the TCR/CD28-driven activation of CD4+ or CD8+ T cells. FasFc 
consistently blocked activation of all primary T cells. To quantify the morphological 
changes, we used FACS analyses looking at activation-dependent changes in cell size 
and granularity. Overall, the morphological changes associated with cellular activation 
were dramatically reduced in the presence of FasFc as compared to cells stimulated in 
the absence of FasFc or in the presence of the Fc control. Thus, while we observed a 
major increase in cell size and granularity upon activation with anti-CD3 and even 
more with co-stimulation, FasFc-treated cells remained almost equal in size compared 
to the medium control. Only a few cells obviously became activated and seemed to 
start to proliferate. In case of the tested activation markers CD25 (IL-2 receptor α-
chain) and CD69 (very early activation, VEA), ligation of CD3 and co-stimulation 
induced the expected strong increase of expression of both antigens with CD25 
expression on CD4+ cells being more dependent on co-stimulation. Clearly, CD25 and 
CD69-induction were almost completely abrogated in the presence of FasFc but not 
Fc control protein. In agreement with the data published for murine CD4+ cells, we also 
observed a strong and almost complete block of cell-cycle progression in the presence 
of FasFc. However, in our hands, the cell cycle blockade was not associated with a 
major increase in cell death (or hypodiploid nuclei as a measure for apoptosis) during 
the observation time of up to four days. Also, CD4+ and CD8+ cells showed an almost 
superimposable reactivity towards FasL ligation. Thus, in contrast to the co-stimulatory 
effect on murine cytotoxic T cells that had been suggested by others, we detected a 
blockage of cell-cycle progression also in CD8+ cells. In fact, Suzuki and Fink had not 
analyzed resting CD8 cells in detail68,69. It should be mentioned, however, that their 
data pointing to an elevated proliferation and effector function and suggesting a 
differential role of FasL engagement on CD4+ and CD8+ cells were obtained with pre-
stimulated populations.  
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In essence, the present work is the first to demonstrate that FasL-engagement is 
capable of altering signal transduction in human T cells. Since it has been suggested 
that Fas-engagement also influences T cell activation139, it seems still unclear whether 
the observed effects of the FasFc fusion protein are due to a blockade of a potentially 
stimulatory Fas signal, due to the induction of an inhibitory signal through FasL or due 
to a FasL-induced inhibition of the TCR-signal as suggested in Figure 5.1. At the 
moment, the first possibility cannot be ruled out completely and may account for some 
aspects of the observed effects.  
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However, the following analyses of signaling events associated with ligation of FasL 
but not Fas strongly suggest that we are monitoring FasL reverse signaling rather than 
blocking Fas signaling. In this regard the analysis of protein tyrosine phosphorylation is 
the most striking effect observed in vitro. In T cell blasts and T cell clones (although 
with a lower amplitude), we clearly saw a decrease in overall tyrosine phosphorylation 
Fig. 5.1. Model for the "negative" costimulatory function of FasL.  
A. "Normal" induction of TCR/CD28-signals in the course of antigen-driven T cell activation. 
B. FasL-dependent block of TCR signaling: by virtue of assembling with a number of cytosolic SH3
domain proteins required for TCR-dependent activation, FasL could alter the TCR/CD3 stimulus in
several different ways. In such a scenario, FasL may serve as a inhibitory molecule that directly
interferes with signal 1 given by the TCR or with signal 2 given by classical costimulatory molecules
such as CD28. As suggested from the data presented here, FasL could also alter the capacity of the
TCR/CD3-associated enzymes and adapters to establish a complete activation complex. 
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in response to CD3-stimulation when cells had been pretreated with crosslinked FasFc 
or anti-FasL mAb. To our knowledge, Fas-ligation is not necessarily associated with 
changes in tyrosine phosphorylation. Thus, even under these conditions, treatment 
with FasFc reflects most probably a direct effect on FasL and not a block of FasL-
binding to Fas. We also know now that FasFc interacts with FasL expressed on 
transfectants since we can use it together with an anti human IgG-Fc antibody for 
detection of FasL expression by flow cytometry (Marcus Lettau, Diploma Thesis). 
Thus, at the moment, our favourite model would be that FasL (binding to all kind of 
SH3 domain containing signaling proteins important for building up the activation 
complex) would simply prevent the induction of TCR-responses by blocking essential 
protein-protein interactions (Fig. 5.1.B). 
 
Another indication for the direct reverse signaling capacity of FasL is the observation 
that purified fusion proteins containing the putative CK1 substrate motif (SSAASS) are 
more heavily phosphorylated by exogenously added CK1 in vitro than fusion proteins 
lacking this motif. In this context it seems relevant that several members of the TNF 
superfamily that have been implicated in reverse signaling in different cellular 
systems137 containing similar motifs that point to an involvement of casein kinase type 
serine threonine kinases in the retrograde signal transduction through these TNF 
ligands. As mentioned before, for TNF it has been shown that mutation of this casein 
kinase motif alters its capacity for reverse signal transduction108. Although still 
preliminary, the observations made in the course of the present thesis suggest that 
besides a crosstalk between receptors such as the TCR/CD3 complex and FasL, the 
molecule may also be linked to yet another, so far unknown signaling machinery. 
Furthermore, the unique "double serine" feature of the CK1 substrate motif in FasL 
indicates a regulation of FasL signaling by additional - yet unknown - kinases and 
phosphatases.  
 
Taken together, the data presented here clearly indicate that FasL might act as an 
inhibitory receptor to prevent T cell activation. This could be of biological importance 
for instance in the context of a primary in vivo T cell activation. Thus, recent studies 
performed by monitoring the fate of T cells in vivo indicated that although T cells enter 
the area where they meet the antigen presenting dendritic cells rapidly, it needs 
around eight to twelve hours until the T cells become activated by close contact with 
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their specific APC140. Since dendritic cells were reported to express Fas141, a ligation 
of FasL on T cells scanning the lymphoid tissue for their antigen could prevent 
premature activation. However, in this scenario FasL expression would be prerequisite 
for the silencer function. This leaves us with the open question whether in vivo and in 
vitro a minimal expression of FasL is sufficient to exert the reverse signal. In fact, so 
far we failed to detect substantial surface expression of FasL at the onset of the 
incubation in the presence of FasFc. Nevertheless the level of FasL expression on 
resting cells and during TCR-driven activation need further investigation, probably 
using amplification systems developed for the detection of proteins expressed at low 
level.  
 
5.2. Defining FasL interacting proteins: the FCH/SH3 family 
To address the question which molecules regulate reverse signal transduction and 
other function of FasL, this laboratory had started to identify FasL interacting proteins 
several years back112,113. Most of the identified interactors are characterized by 
containing a SH3 or WW domain likely to mediate the FasL interaction by binding to 
the proline-rich domain located in the membrane proximal cytosolic portion of FasL. 
Since it had been noted in the meantime that FasL is stored in specialized lysosomal 
vesicles, we started with a focus on proteins like FBP17 and PACSIN that had been 
implicated in vesicular transport or actin dynamics in other systems. As described 
earlier, FBP17 and PACSIN2 were identified as FasL interactors by Ghadimi et al.113. 
They belong to a larger family of proteins with a similar domain structure, therefore 
termed FCH/SH3 family. Besides PACSIN2 and FBP17, the PACSIN2 isoforms 
PACSIN1 and PACSIN3, CD2BP1, CIP4, RhoGAP C1 and two hypothetical proteins 
(FLJ00007 and KIAA0456) belong to this family. Most if not all these proteins are 
involved in the regulation of actin dynamics, cytoskeletal reorganization and 
intracellular trafficking in different cellular systems. For example, PACSIN2 has been 
implicated in lysosomal transport by interacting with several proteins (e.g. dynamin) at 
the lysosomal basis (M. Plomann, personal communication). Interestingly, all tested 
SH3 domains of the FCH/SH3 proteins were capable of interacting with FasL in in vitro 
"pull-down" assays. Importantly, also the tested full length proteins bound to FasL. Of 
course, the interaction site was confirmed to be SH3 domain of the respective 
interaction partner. In case of FBP17 and PACSIN2, deletion (FBP17) or mutation 
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(PACSIN2) of the SH3 domains completely blocked the association with FasL in "pull 
down" experiments. Importantly, when overexpressed together with FasL, FBP17 and 
all the PACSIN isoforms as well as CD2BP1 and CIP4 co-precipitated FasL from 
cellular lysates. 
 
A major task of the present work was to analyze how the intracellular localization of 
FasL maybe altered only co-expressed with FasL-interacting proteins. As has been 
reported, hematopoietic and non-hematopoietic cells differ in the lysosomal 
compartment. This is also reflected at the level of FasL expression. In non-
hematopoietic cells (including HeLa, HACAT and 293T) FasL is obviously sorted 
directly to the cell surface whereas in hematopoietic cells (Jurkat, HUT78 and RBL), 
FasL localizes to granular vesicular structures. 
 
When FCH/SH3 proteins were expressed in 293T cells, the PACSINs appeared mostly 
cytosolic. FBP17 seemed to be expressed in the cytosol as well as in compartments 
close to the membrane. Similarly, CD2BP1 and CIP4∆CC were also localized in 
different distribution in cytosolic to intracellular structures. Co-expression with FasL 
changed the localization of FasL dramatically leading the molecule from the 
membrane to the lysosomal compartment. Only in the case of the PACSIN2 mutant 
which did not co-localize with FasL, the recruitment to the lysosomes was not obvious. 
Importantly, the lysosomal localization was confirmed by partial co-localization with 
Cathepsin D as a marker for lysosomes/endosomes. The most striking effects were 
seen in HeLa cells: FasL co-expression with PACSIN2 lead both molecules to 
lysosomes whereas expression with PACSIN2 carrying the point mutation in the SH3 
domain completely abrogated co-localization and resulted in an almost complete 
surface association of FasL. Of note, we did never observe a 100% overlap of 
lysosomal, FasL and FCH/SH3 protein staining. In RBL cells, we also observed 
colocalization. In most cases, when wild-type DNA was transfected, we observed an 
increase in size of the granular structures. Clearly, this was not seen when SH3 
domain lacking (FBP17) or mutated (PACSIN2) proteins were co-expressed. To us 
this indicated that in cells of the hematopoietic lineage in which FasL is "automatically" 
located into the lysosomal compartment also in single transfectants, the additional 
presence of "sorting proteins" somehow leads to a further accumulation of the 
respective proteins in or around the vesicles. 
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The suggested function of FBP17 and PACSINs in different systems has been 
described in the introduction. There is still some controversy as to whether the three 
isoforms of PACSIN are also functionally expressed in neuronal versus other cells. 
However, we were able to amplify the SH3 domain and full-length proteins from T cell 
lines (HUT78) or T cell blasts. The expression of CD2BP1 and CIP4 is restricted to 
hematopoietic cells124,142. CD2BP1 is a 415 amino acid long cytosolic adaptor protein 
expressed in T cells that has been proposed to be important in regulating T cell 
activation by modulation of CD2 activity143,144. In these cells, CD2BP1 regulates 
cytoskeletal organization142 and also seems to be involved in the formation of the 
immunological synapse145. As recently described, in this context, CD2BP1 acts 
downstream of CD2/CD2AP to link CD2 engagement to the Wiskott-Aldrich syndrome 
protein (WASP)-evoked actin polymerisation required for synapse formation and T cell 
activation145. CD2BP1 is also named PSTPIP1 (proline, serine, threonine phosphatase 
interacting protein) based on its interaction with a PEST family protein tyrosine 
phosphatase146. PTP PEST in turn is expressed in hematopoietic tissues and has 
been reported to negatively regulate lymphocyte activation142: The interaction of 
CD2BP1 with (murine) PTP PEST has been described to be mediated by the coiled-
coil domain of CD2BP1147. In man, mutations in CD2BP1 have been shown to disrupt 
the binding to PTP PEST and made responsible for the PAPA syndrome, an auto-
inflammatory disorder148. Our data showed that CD2BP1 might also be involved in the 
lysosomal targeting or transport of FasL. Importantly, CD2BP1 has been found as an 
interactor for murine FasL in a yeast-two-hybrid screen by our collaborators Wiebke 
Baum and Martin Zörnig (Frankfurt). However, more works is needed to establish the 
role of CD2BP1 in lysosomal targeting or even transport to the immunological 
synapse.  
 
The cdc42-interacting protein4 (CIP4) was first described as an interactor of a 
constitutively active mutant of cdc42124. Besides interacting with cdc42, CIP4 also 
mediates the recruitment of WASP to microtubules125. It interacts with Src kinase Lyn 
to phosphorylates WASP in a process regulated by cdc42149 and with huntingtin150, an 
adaptor protein involved in neurodegenerative Huntington’s disease. 
 
Besides the SH3 domain, FCH/SH3 proteins also contain so-called FCH domains 
(=Fes/CIP4 homology). The FCH domain was first described as a region of homology 
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between the Fps/Fes/Fer protein tyrosine kinases (PTK) and the Cdc42-interacting 
protein, CIP4124. Blast analyses within protein databases reveal the presence of FCH 
domains in numerous proteins, which fall into three classes: Fer and Fps/Fes protein 
kinases, adapter-like proteins, and RhoGTPase activating proteins. The FCH/SH3 
family proteins that we analyzed are adapter-like or RhoGTPase activating proteins. 
FCH domains are mostly implicated in the regulation of the cytoskeleton. For example, 
the FCH domain of CIP4 was reported to bind to microtubules125. More recently, the 
FCH domain in Fes was reported to play an important role in microtubule dynamics 
including microtubule nucleation and bundling126. In the context of FasL, co-expression 
indicates that the protein-protein interaction is sufficient for lysosomal targeting. Thus, 
it is possible that the FCH domains of these proteins are also involved in lysosomal 
targeting or cytoskeleton-dependent vesicular transport.  
 
Taken together, we are convinced that the FCH/SH3 proteins identified as interactors 
are capable of changing the subcellular distribution of FasL (Fig. 5.2.). However, 
further work is necessary to evaluate the role of the individual members of the family in 
T cells and NK cells. 
 
5.3. FasL interacts with Nck1: linking the cytoskeleton and the TCR/CD3 
complex? 
In cytotoxic T cells (and NK cells), FasL is expressed and synthesized upon primary 
stimulation and then directed to and stored in specialized secretory 
lysosomes/granules21,22. As mentioned, in activated cytotoxic T cells, FasL is a 
transmembrane compound of these secretory granules or lysosomes which (in man) 
also contain granzymes A, B, H, K and M, pore-forming perforin-monomers and 
granzymes151. Upon interaction with a target cell, the lipid bilayer of the secretory 
lysosomes fuses with the plasma membrane, thereby releasing the soluble lysosomal 
components and presenting mFasL on the cell surface22,23. This trigger of target cell 
apoptosis has been referred to as the “kiss of death”152. This cytoskeletal association 
may also play a role in FasL transport to the cell membrane. Like various other protein 
that were identified as FasL interactors, two adaptor proteins that bound to FasL via 
SH3 domains attracted our attention in the context of vesicular transport or 
cytoskeletal movement. The interaction of FasL with Grb2 has been verified by various 
assays before112,113. In the present work, we thus focused on Nck1 and followed its 
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fate when co-expressed with FasL or in an in vivo stimulation when cytotoxic T cells 
meet their cognate target cells. Nck1 is an adapter protein of 377 amino acids that is 
built of one c-terminal SH2 and three SH3 domains. It was shown to constitutively 
associate with the active γ2 isoform of casein kinase 1 (CK1-γ2)133 and therefore could 
be involved in recruitment of the kinase into proximity of FasL as a putative substrate. 
The second function of Nck1 is the regulation of cytoskeletal assembly through 
interaction with the Wiskott-Aldrich syndrome protein WASP127, the WASP interacting 
protein WIP128, WASP-family verprolin homologous protein WAVE1129, the Centaurin-α 
family of PIP3 binding proteins130, the p21-activated kinase PAK1131, the ε-chain of 
CD3132 and others. 
 
When following FasL expression in normal activated T cells, we observed an 
intracellular localization within the putative secretory granules. Upon activation with 
TPA/ionomycin, we saw a rapid disintegration of these granules and later a diffuse 
surface expression of FasL. Interestingly, when analyzing the kinetics of surface 
expression, we detected a clear biphasic pattern in all tested T cells and clones 
indicating two waves of FasL expression in activated T cells. The first peak was seen 
after short-term stimulation (10 minutes) and most probably reflects a PKC/Ca2+ 
induced reorganization of the cytoskeleton leading to transport of FasL to the surface. 
The second maximum is reached after 2 hours and is dependent on de novo protein 
synthesis and lysosomal transport (Marcus Lettau, Diploma Thesis). 
 
To address the question whether Nck1 is involved in this process, we followed the 
expression pattern of both molecules in transfectants and normal T cells. Before, we 
proved the interaction between Nck1 and FasL using the different constructs that we 
obtained from our collaborators Louise Larose (Quebec) and Michael Way (London). 
Clearly, in vitro binding was seen with full length Nck1 and with the second and third 
SH3 domain. As had been described before132, all SH3 domains seem to cooperate 
since individual mutation in all three domains reduced the binding to FasL. We also 
show co-precipitation of FasL from co-transfectants and conversely co-precipitation of 
Nck1 with anti-FasL antibodies. 
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Upon transfection of 293T cells, we found a co-localization of wt Nck1 and SH2 
mutated Nck1 with FasL. From parallel staining for cathepsin D, we knew that both 
molecules were associated with the lysosomal compartment. As expected from the in 
vitro binding studies, mutations in all three SH3 domains influenced binding and co-
localization. However, all three individual mutations almost completely abrogated co-
localization indicating once more that all SH3 domains cooperate for function of Nck1. 
Interestingly, while Nck1 was mostly expressed as a diffusely distributed cytoplasmic 
protein in single transfectants, in double-transfectants, it was located in part in the 
proximity of lysosomes also occupied by FasL (and Cathepsin D or lamp1). Since it 
had been reported that upon TCR stimulation, Nck1 recruits other proteins to the 
TCR/CD3 complex re-assembling the cytoskeleton around the immunological 
synapse132, we wanted to investigate a potential co-localization in T cells that were 
exposed to target cells. Before, we observed in superantigen-reactive T cell clones 
that FasL, Cathepsin D and Nck1 rapidly co-localized in pseudopodium-like 
protrusions that formed after exposure to superantigen. This process was sensitive to 
inhibitors of actin polymerisation (latrunculin A or cytochalasin D) indicating an major 
contribution of regulators of cytoskeleton dynamics. Also, we proved the synapse 
formation by phalloidin staining of the "actin-disk" that is seen between T cells and 
target cells. Once again, this synapse formation and phalloidin staining was sensitive 
to latrunculin A or cytochalasin D. 
 
Ultimately, we analyzed CD8+ T cells and γδ T cells that were incubated with their 
cognate target cells (EBV transformed B cells and MeWo tumor cells, respectively). In 
both cases, we observed a directed movement of all molecules (FasL, Nck1 and 
Cathepsin D) to the area of contact. This effect could also be inhibited by prevention of 
actin filament formation. Taken together, these data indicate that Nck1 may in fact be 
involved in the TCR/CD3-dependent directed movement of FasL to the immunological 
synapse (Fig. 5.2.). However, in the future the specificity of this interaction needs to be 
further addressed e.g. by siRNA approaches since other molecules (CD2BP1 and 
Grb2) that interact with FasL could also play a role in the context of synapse formation. 
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5.4. Other FasL interacting proteins: FLAFs 
As part of the present work, we also demonstrated that FasL is capable of interacting 
with three "Fas-ligand associated factors" (FLAF1-3) that had been deposited in the 
NCBI database by Hachiya and coworkers in 1996 (accession numbers: AAB93495, 
AAB93496, AAB93497). They were identified in a yeast two-hybrid screen by using the 
cytoplasmic portion FasL as bait. The proteins contain either a WW domain (FLAF1) or 
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Fig. 5.2. FasL interacting proteins - from secretory granules to the immunological synapse.
In cytotoxic T cells and NK cells, FasL is targeted to the so-called secretory granules/lysosomes.
Besides FasL, these lysosomes contain other cytotoxic molecules such as granzymes and
perforins which in concert contribute to an effective target cell lysis. Of note, targeting of FasL to
these lysosomes strictly depends on the proline-rich domain (PRD) within the cytoplasmic tail of
the molecule. In this context, members of the FCH/SH3 family (including FBP17, PACSINs,
CD2BP1 and others) are candidates for directing the localization and transport of FasL (and/or
secretory lysosomes in general). Most proteins of this family are involved in actin cytoskeleton
reorganization and protein/organelle trafficking. Other interactors for FasL are the small adapter
proteins Grb2 and Nck1. Therefore, an attractive model would be that the PRD is not only required
for lysosomal targeting but also for transport and fusion of these lysosomes to the area where the
immunological synapse is formed. This could be followed by the release of the various cytolytic
factors and by FasL cleavage in the presence of a metalloproteinase (e.g. matrilysin, MMP-7).
Whether the sFasL induces or inhibits apoptosis then depends on the potential to form active
multimers. The complex biology of FasL is further underscored by the fact that it has been found
to act as a "negative" or "positive" costimulatory molecule for T cells. Whether the same
(FCH/SH3-family, Grb2 or Nck1) or other (e.g. CK1, PI 3-kinases or Src kinases) FasL- interacting
molecules are involved in this aspect, is still open.  
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one or more SH3 domains (FLAF2,3). Except a note that FLAFs might regulate FasL 
stability, so far there are no further results published. Sequence comparison with novel 
entries in protein databases reveals that FLAF1 forms part of the formin binding 
protein 11 (FBP11, also called the huntingtin-interacting protein A, HYPA), FLAF2 is 
part of the c-Cbl-associated protein SH3P12 = "sorbin and SH3 domain containing 1" 
(containing 3 SH3 domains), and FLAF3 represents a portion of the BAI1-associated 
protein 2 (BAP2β, with a single SH3 domain).  
 
FBP11/FLAF1 is one of several very proteins that bind to formins, proteins involved in 
murine limb and kidney development. FBP11 contains two WW domains, which bind to 
proteins with proline-motifs. Recently, HYPA, the human ortholog of murine FBP11, 
was identified and shown to interact with the N terminus of the huntingtin protein153,154. 
A more recent report shows that FBP11 regulates nuclear localization of N-WASP and 
inhibits N-WASP-dependent microspike formation155. Thus, this protein might also be 
involved in cytoskeleton reorganization. Concerning FasL, at the moment GST "pull 
down" analyses with isolated WW domains confirmed that WW domains of 
FBP11/FLAF1 are capable of interacting with FasL. SH3P12/FLAF2 has been 
demonstrated in a, so far single report, as a binding partner for l-afadin and vinculin, 
two isoforms of a novel actin filament (F-actin)-binding protein and is localized at cell-
cell and cell-matrix junctions156. Concerning BAP2β/FLAF3, it is known that the SH3 
domain of BAP2 interacts with the proline-rich cytoplasmic portion of BAI1 and co-
localizes it to the cytoplasmic membrane157. Miki et al. found that FLAF3 (also termed 
insulin receptor substrate protein 53 (IRSP53) by this group) is essential for RAC-type 
G-proteins to induce membrane ruffling, probably due to a recruitment of WAVE2, 
which in turn stimulates actin-polymerization mediated by the ARP2/3 complex158.  
 
Based on RT-PCR, we found that all FLAFs or the corresponding proteins are 
expressed in T cell blasts and T cell lines (HUT 78). The distribution of myc-tagged 
SH3P12/FLAF2 and BAP2β/FLAF3 is mainly in cytosolic with some staining in 
membrane ruffles in 293T transfectants. While co-expressed, they showed strong co-
localization with FasL at the plasma membrane. The biological role of the interactions 
remains to be elucidated. 
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6. Summary 
FasL, a type II transmembrane protein of the TNF superfamily, acts as a death factor 
and a costimulatory molecule. In the course of this thesis, the retrograde signaling of 
FasL could be demonstrated for the first time in human T cell populations. With the 
help of a FasFc fusion protein used as a binding partner for FasL, it was demonstrated 
that FasL engagement results in a severe block of T cell activation. This was reflected 
in reduced proliferation, a block in expression of activation markers and a marked 
reduction in cell-cycle progression without increased cell death. Importantly, inhibition 
was seen in purified whole T cells as well as in CD4+ and CD8+ subpopulations and 
FasL needed to be crosslinked to achieve the effects. 
FasL contributes to immune selection, immune response termination and the 
establishment of immune privilege. FasL expression has to be tightly regulated to 
prevent unwanted damage within the immune system. The protein expression differs 
in individual immune cell subsets. In cytotoxic T cells and NK cells, FasL is targeted to 
and stored in so-called secretory lysosomes. This association strictly depends on the 
presence of a proline-rich domain (PRD) in the cytosolic part of FasL. Several putative 
interactors for this PRD of FasL had been identified in vitro. A second main focus of 
the present study was the detailed analyses of several of these interactions in vitro 
and in vivo. Starting with FBP17 and PACSIN2, two of the proteins that had been 
previously identified as FasL interactors, and extending the analysis to the whole 
FCH/SH3 family of closely related proteins, it was demonstrated that all members of 
this family can interact with FasL in vitro and in vivo. Furthermore, most if not all 
FCH/SH3 proteins tested dramatically changed the subcellular localization of FasL 
when co-expressed in non-hematopoietic cells indicating a major role of these 
interactors in guiding FasL to the lysosomal compartment.  
FCH/SH3 proteins might also play a role on the way of FasL to the immunological 
synapse. However, in this context, it could be demonstrated that the adapter protein 
Nck1 co-localizes with the FasL and upon stimulation of T cells both molecules move 
to the area of target cell contact. Since Nck1 has been described as a direct link of 
actin-dependent recruitment of molecules to the immunological synapse, the present 
data suggest that the TCR-triggered recruitment of Nck1 also results in a directed 
transport of FasL and associated secretory lysosomes. 
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Der Fas Ligand (FasL) ist ein Transmembran-Protein der TNF-Familie und fungiert als 
Todesfaktor und als ko-stimulatorisches Molekül. Im Rahmen der vorliegenden Arbeit 
wurde seine Funktion als retrograder Signalgeber in humanen T-Zell-Populationen 
erstmals gezeigt. Nach Bindung eines FasFc Fusionsproteins beobachteten wir eine 
FasL-vermittelte Inhibition der T-Zell-Aktivierung. Dies äußerte sich in unter anderem 
in einem Block der Expression von Aktivierungsmarkern und einer deutlichen 
Reduktion der Zellzyklus-Progression ohne erhöhte Induktion von Zelltod. Im 
Gegensatz zu publizierten Daten aus Mausmodellen, traten die Effekte gleichermaßen 
in angereicherten T-Zellen wie auch in isolierten CD4+ and CD8+ T-Zellen auf. In allen 
Fällen war eine Kreuzvernetzung von FasL erforderlich. 
FasL ist an der Selektion von Immunzellen ebenso beteiligt wie an der Beendigung der 
Immunantwort oder an der Etablierung von Immunprivileg. Die FasL-Expression muss 
wohl reguliert sein, um Störungen innerhalb des Immunsystems zu vermeiden. Die 
Expression des Proteins differiert in verschiedenen Zellpopulationen. In zytotoxischen 
T- und NK-Zellen wird der FasL zu sekretorischen Lysosomen geleitet und dort 
gespeichert. Die Assoziation hängt von der prolinreichen Domäne im 
zytoplasmatischen Anteil von FasL ab. Für diese Region wurden in Vorarbeiten eine 
Reihe von potenziellen Interaktionspartnern beschrieben. Im zweiten Schwerpunkt der 
vorliegenden Untersuchung sollten diese Interaktionen in vitro und in vivo näher 
analysiert werden. Beginnend mit den FasL-bindenden Proteinen FBP17 und 
PACSIN2 wurde letztendlich für die ganze "'FCH/SH3"-Familie gezeigt, dass alle 
Mitglieder mit FasL interagieren können. Alle untersuchten Proteine dieser Familie 
beeinflussten die subzelluläre Verteilung des FasL, was die Bedeutung der FCH/SH3-
Proteine für die lysosomale Lokalisation des FasL unterstreicht.   
Die FCH/SH3 Proteine könnten zudem eine Rolle bei der Rekrutierung des FasL zur 
immunologischen Synapse spielen. Im Rahmen der Untersuchungen wurde gezeigt, 
dass das Adapterprotein Nck mit FasL kolokalisiert und dass beide Moleküle 
zusammen zur Region des Zielzell-Kontaktes verlagert werden. Da Nck kürzlich als 
direktes Bindeglied zwischen Aktin-Zytoskelett und der immunologischen Synapse 
beschrieben wurde, deuten die Befunde darauf hin, dass die TZR-induzierte 
Umlagerung von Nck mit einen gerichteten Transport von FasL und möglicherweise 
den sekretorischen Lysosomen zur immunologischen Synapse assoziiert ist. 
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